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1. TASKS OF MEDICAL GENETICS. 
SYNDROMOLOGICAL ANALYSIS. BIRTH DEFECTS 
 
I. A few words about Medical Genetics 
Medical genetics is the specialty of medicine that 
involves the diagnosis and management of hereditary disorders. 
Medical genetics differs from human genetics in that human 
genetics is a field of scientific research that may or may not 
apply to medicine, but medical genetics refers to the 
application of genetics to medical care. For example, research 
on the causes and inheritance of genetic disorders would be 
considered within both human genetics and medical genetics, 
while the diagnosis, management, and counseling of 
individuals with genetic disorders would be considered part of 
medical genetics. 
In contrast, the study of typically non-medical 
phenotypes such as the genetics of eye color would be 
considered part of human genetics, but not necessarily relevant 
to medical genetics (except in situations such as albinism). 
Genetic medicine is a newer term for medical genetics and 
incorporates areas such as gene therapy, personalized medicine, 
and the rapidly emerging new medical specialty, predictive 
medicine. 
Medical genetics encompasses many different areas, 
including clinical practice of physicians, genetic counselors, 
and nutritionists, clinical diagnostic laboratory activities, and 
research into the causes and inheritance of genetic disorders. 
Examples of conditions that fall within the scope of medical 
genetics include birth defects and dysmorphology, mental 
retardation, autism, and mitochondrial disorders, skeletal 
dysplasia, connective tissue disorders, cancer genetics, 
teratogens, and prenatal diagnosis. Medical genetics is 
increasingly becoming relevant to many common diseases. 
Overlaps with other medical specialties are beginning to 
emerge, as recent advances in genetics are revealing etiologies 
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for neurologic, endocrine, cardiovascular, pulmonary, 
ophthalmologic, renal, psychiatric, and dermatologic 
conditions. 
 Medical genetics consists of several parts: 
1. Clinical genetics.  Clinical genetics is the practice of 
clinical medicine with particular attention to hereditary 
disorders. Referrals are made to genetics clinics for a variety of 
reasons, including birth defects, developmental delay, autism, 
epilepsy, short stature, and many others. Examples of genetic 
syndromes that are commonly seen in the genetics clinic 
include chromosomal rearrangements, Down syndrome, 
DiGeorge syndrome (22q11.2 Deletion Syndrome), Fragile X 
syndrome, Marfan syndrome, Neurofibromatosis, Turner 
syndrome, and Williams syndrome. 
2. Metabolic/biochemical genetics. Metabolic (or bio-
chemical) genetics involves the diagnosis and management of 
inborn errors of metabolism in which patients have enzymatic 
deficiencies that perturb biochemical pathways involved in 
metabolism of carbohydrates, amino acids, and lipids. 
Examples of metabolic disorders include galactosemia, 
glycogen storage disease, lysosomal storage disorders, 
metabolic acidosis, peroxisomal disorders, phenylketonuria, 
and urea cycle disorders. 
3. Cytogenetics. Cytogenetics is the study of 
chromosomes and chromosome abnormalities. While 
cytogenetics historically relied on microscopy to analyze 
chromosomes, new molecular technologies such as array 
comparative genomic hybridization are now becoming widely 
used. Examples of chromosome abnormalities include 
aneuploidy, chromosomal rearrangements, and genomic 
deletion/duplication disorders. 
4. Molecular genetics. Molecular genetics involves the 
discovery of and laboratory testing for DNA mutations that 
underlie many single gene disorders. Examples of single gene 
disorders include achondroplasia, cystic fibrosis, Duchenne 
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muscular dystrophy, hereditary breast cancer (BRCA1/2), 
Huntington disease, Marfan syndrome, Noonan syndrome, and 
Rett syndrome. Molecular tests are also used in the diagnosis 
of syndromes involving epigenetic abnormalities, such as 
Angelman syndrome, Beckwith-Wiedemann syndrome, Prader-
Willi syndrome, and uniparental disomy. 
5. Mitochondrial genetics. Mitochondrial genetics 
concerns the diagnosis and management of mitochondrial 
disorders which have a molecular basis but often result in 
biochemical abnormalities due to deficient energy production. 
 
One of the most important threats for human’s health is 
the genetic diseases.  
Genetic disease is a disorder caused by genetic factors 
and especially abnormalities in the human genetic material 
(genome).  
Types of (human) genetic diseases are:  
1. Single-gene/monogenic genetic diseases. 
In this category the starting point is a mutation/change 
in one gene. Some of these are sickle cell anemia, cystic 
fibrosis, Aicardi Syndrome, Huntington’s disease. 
2. Multifactorial/polygonic genetic diseases. 
The second type of human genetic diseases is caused by 
mutations in more than one gene. Many well-known chronic 
diseases are multifactorial genetic diseases. Everybody knows 
Alzheimer, diabetes, obesity and arthritis. Besides many cancer 
types are caused by multi mutations. 
3. Chromosomal genetic diseases. 
Chromosomes are big DNA molecules composed from 
genes. The chromosomes are located in the cell nucleus. 
Abnormalities in the structure, number (and not only) of the 
chromosomes can cause some of the most dangerous genetic 
disorders. This type of disorders seems to be much easier to 
observe because they are, sometimes, detected by examination 
with microscope. Down syndrome is the most well-known 
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disease caused by chromosomal abnormalities. There is a third 
copy of chromosome – 21 in this disorder (there are two copies 
of each chromosome in the cells of healthy people). 
Chromosomal diseases can be also caused by segments and 
joins of parts of chromosomes. 
4. Mitochondrial genetic diseases. 
It is not a common situation. Mitochondrial DNA is a 
DNA molecule found in the mitochondria (out of the nucleous) 
– a necessary organelle for cellular respiration. Mutations in 
the mitochondrial DNA can also cause undesirable 
abnormalities. 
 
II. Phenotype 
The human genome has approximately 38 000 genes 
which are the individual units of heredity of all traits. The 
genes are organized into long segments of deoxyribonucleic 
acid (DNA), which, during cell division, are compacted into 
intricate structures with proteins to form chromosomes. The 
function of genes is the production of structural proteins and 
enzymes. This occurs through a series of events, termed 
transcription, processing, and translation.  
Phenotype is the total observable physical traits of an 
individual (organism or cell). Mayr notes that these observable 
features include anatomical, physiological, biochemical, and 
behavioral characteristics. The term can also be used in 
reference to one particular trait or characteristic that is 
measurable and is expressed in only a subset of individuals 
within that population. For example, blue eye color, aggressive 
behavior, bilateral symmetry, and length of antennae are 
phenotypic traits. 
The phenotype of a developing or developed organism 
is held to be the result of interaction between the inherited 
genotype (the genetic makeup of the individual), transmitted 
epigenetic factors (those changes in genome function that do 
not alter the nucleotide sequence within the DNA), and non-
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hereditary environmental variation. Some phenotypes are 
controlled entirely by the individual’s genes. Others are 
controlled by genes but are significantly affected by non-
genetic or environmental factors. Still other phenotypes are 
entirely non-genetic, for example, a person’s language or 
physical traits that were altered by surgery. 
Each human being has a unique phenotype. Even 
identical twins, who have the same genotypes, exhibit 
differences (such as fingerprints or behavioral characteristics) 
because of non-genetic factors. The process of sexual 
reproduction, crossing over, mutations, and environmental and 
other non-genetic influences all help assure that individuals 
throughout history are unique. Religions also emphasize the 
importance of one’s spiritual aspect (soul, spirit) and spiritual 
environment (such as the history of past actions) as influences 
on the nature of a person, versus an over-emphasis on genotype 
and physical influences. From the point of view of religion, as 
a unique manifestation of God’s nature, each person can offer a 
unique joy to God and to others. 
Geneticists use easily observable phenotypes to deduce 
an organism’s genotype, and analyze complex phenotypes to 
help hypothesize about how individual genes function.  
Genotype and phenotype 
The terms “genotype” and “phenotype” were created by 
Wilhelm Johannsen in 1911. A genotype is the genetic makeup 
(set of genes) of an individual organism or cell. Genes are the 
units of heredity in living organisms and are encoded in the 
organism’s genetic material – those segments of DNA that 
cells transcribe into RNA and translate, at least in part, into 
proteins. 
An organism’s genotype is a major (the largest by far 
for morphology) influencing factor in the development of its 
phenotype, but it is not the only one. For many traits, the 
genotype may set the potential and limits for phenotypic 
expression, but environmental influences can be major. 
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Although there has been a historical debate regarding 
the prominence that should be given to “nature” (genes) versus 
“nurture” (environment), the consensus is that most 
characteristics of an organism are affected by both factors. For 
example, the presence or absence of nutrients will affect plant 
growth and health. The phrase norm of reaction refers to the 
amplitude of variation of a phenotype produced under different 
environmental conditions. 
Many phenotypes also are determined by multiple 
genes. Thus, the identity of one or a few alleles of an organism 
does not always enable prediction of its phenotype. 
Even two organisms with identical genotypes normally 
differ in their phenotypes. One experiences this in everyday life 
with monozygous (i. e. identical) twins. Identical twins share 
the same genotype, since their genomes are identical; but they 
never have the same phenotype, although their phenotypes may 
be very similar. This is apparent in the fact that their mothers 
and close friends can tell them apart, even though others might 
not be able to see the subtle differences. Furthermore, identical 
twins can be distinguished by their fingerprints which are never 
completely identical. Of course, personality differences can be 
substantial. 
The concept of phenotypic plasticity describes the 
degree to which an organism’s phenotype is determined by its 
genotype. A high level of plasticity means that environmental 
factors have a strong influence on the particular phenotype that 
develops. If there is little plasticity, the phenotype of an 
organism can be reliably predicted from knowledge of the 
genotype, regardless of environmental peculiarities during 
development. An example of high plasticity can be observed in 
larval newts – when these larvae sense the presence of 
predators, such as dragonflies, they develop larger heads and 
tails relative to their body size and display darker pigmentation. 
Larvae with these traits have a higher chance of survival when 
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exposed to the predators, but grow more slowly than other 
phenotypes. 
In contrast to phenotypic plasticity, the concept of 
genetic canalization addresses the extent to which an 
organism’s phenotype allows conclusions about its genotype. A 
phenotype is said to be canalized if mutations (changes in the 
genome) do not noticeably affect the physical properties of the 
organism. This means that a canalized phenotype may form 
from a large variety of different genotypes, in which case it is 
not possible to exactly predict the genotype from knowledge of 
the phenotype (i. e. the genotype-phenotype map is not 
invertible). If canalization is not present, small changes in the 
genome have an immediate effect on the phenotype that 
develops. 
Phenotypic variation 
Phenotypic variation (due to underlying heritable 
genetic variation) is a fundamental prerequisite for a 
population’s adaptation to its environment due to natural 
selection. The “fitness” of an organism is a high-level 
phenotype determined by the contributions of thousands of 
more specific phenotypes. Without phenotypic variation, 
individual organisms would all have the same fitness, and 
changes in phenotypic frequency would proceed without any 
selection (randomly). 
The interaction between genotype and phenotype has 
often been conceptualized by the following relationship: 
genotype + environment → phenotype 
A slightly more nuanced version of the relationship is: 
genotype + environment + random-variation → 
phenotype 
An example of the importance of random variation in 
phenotypic expression is Drosophila melanogaster in which the 
number of eyes may vary (randomly) between left and right 
sides in a single individual as much as they do between 
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different genotypes overall, or between clones raised in 
different environments. 
A phenotype is any detectable characteristic of an 
organism (i. e., structural, biochemical, physiological, and 
behavioral) determined by an interaction between its genotype 
and environment. According to the autopoietic notion of living 
systems by Humberto Maturana, the phenotype is 
epigenetically being constructed throughout ontogeny, and we 
as observers make the distinctions that define any particular 
trait at any particular state of the organism’s life cycle. 
The concept of phenotype can be extended to variations 
below the level of the gene that effect an organism’s fitness. 
For example, silent mutations that do not change the 
corresponding amino acid sequence of a gene may change the 
frequency of guanine-cytosine base pairs (GC content). These 
base pairs may have a higher thermal stability (“melting 
point”) than adenine-thymine, a property that might convey, 
among organisms living in high temperature environments, a 
selective advantage on variants enriched in GC content. 
 
III. Physiologic Basis of Birth Defects 
 The development of birth defects is greatly dependent 
on the gestational age, nature of the teratogens and the intensity 
and duration of exposure.  The reader is strongly encouraged to 
review human development, particularly embryology as it 
relates to organogenesis, to better understand how and when 
environmental factors may influence fetal development.  Organ 
systems differ in the timing and duration of formation which 
results in marked differences in susceptibility.  For example, 
the cardiovascular system undergoes a lengthy and complex 
developmental phase which probably explains why this organ 
system has the highest incidence for birth defects.  Also as 
general rule, significant early insults (less than 8 gestational 
weeks) result in spontaneous miscarriages, whereas exposure 
later in the gestation (typically after organogenesis or 
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approximately 14–16 weeks of gestation) has the least effect.  
There are, however, many exceptions to these basic rules. 
 It is essential to understand the pathophysiologic 
mechanisms for fetal maldevelopment which may be divided 
into malformation, deformation, disruption or dysplasia.   
Malformation 
A malformation is a primary structural defect occurring 
during the development of an organ or tissue. Most 
malformations have occurred by 8 weeks of gestation.  
An isolated malformation, such as cleft lip and palate, 
congenital heart disease or pyloric stenosis can occur in an 
otherwise normal child. 
Multiple malformation syndromes comprise defects in 
two or more systems and many of them are associated with 
mental retardation. 
Disruption 
A disruption defect implies that there is destruction of a 
part of a fetus that had initially developed normally. 
Disruptions usually affect several different tissues within a 
defined anatomical region. 
Deformation 
Deformations are due to abnormal intrauterine 
moulding and give rise to deformity of structurally normal 
parts. Deformations usually involve the musculoskeletal 
system and may occur in fetuses with underlying congenital 
neuromuscular problems such as spinal muscular atrophy and 
congenital myotonic dystrophy. This is illustrated in the 
characteristic pattern of abnormalities including the abnormal 
facies, pulmonary hypoplasia, and limb contractures that result 
from prolonged oligohydramnios, either secondary to renal 
agenesis (Potter syndrome) or premature rupture of membranes 
(Potter sequence).   
Dysplasia 
Dysplasia refers to abnormal cellular organisation or 
function within a specific organ or tissue type. Most dysplasias 
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are caused by single gene defects, and include conditions such 
as skeletal dysplasias and storage disorders from inborn errors 
of metabolism. 
 IV. The physical examination in clinical genetics 
The physical examination is a valuable tool in medical 
practice that provides an objective supplement to historical 
information. To understand the special nature of the “genetic” 
physical exam, one must first recognize that the primary goal 
of a medical genetic evaluation is to identify a unifying 
etiology for seemingly unrelated birth defects, developmental 
problems, or other abnormal findings present in a fetus, child, 
or adult. Some may question the benefits of making a genetic 
diagnosis, as there are very few “cures” for such conditions. 
However, it is only by establishing a correct diagnosis that 
appropriate clinical management can be provided, along with 
accurate prognostic and recurrence risk counselling. 
Understanding the pathogenesis of a patient’s problems can 
further help families begin to cope with guilt they may feel 
about “why” their child has a particular problem and can direct 
families to contact appropriate support groups. 
The genetic physical exam relies heavily on the art of 
dysmorphology, defined as the study of abnormal form. A 
detailed analysis of body structure is employed to detect 
potential embryologic deviations from normal development. 
While the actual physical examination is similar to the general 
medical examination, much closer attention is given to form, 
size, proportion, positioning, spacing, and symmetry. Indeed, 
precise observation and accurate description of all physical 
features is the cornerstone of the genetic dysmorphology exam. 
A genetic diagnosis may subsequently be reached through 
careful collation, interpretation, and categorization of any 
physical differences present. 
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Categorization of physical abnormalities 
Physical exam findings that are indicative of a genetic 
diagnosis may be of varying clinical relevance. Major 
anomalies are structural alterations arising during embryologic 
development that have severe medical or cosmetic 
consequences and typically require therapeutic intervention. 
Examples include congenital heart defects, neural tube defects, 
and cleft lip or palate. Minor anomalies, in contrast, are 
medically and cosmetically insignificant departures from 
normal development that do not require significant surgical or 
medical treatment and have no risk for long-term sequelae. 
Minor external anomalies most commonly are found in areas 
where structures are most complex and variable, such as in the 
face, auricles, hands, and feet. Examples include wide-set eyes, 
low-set ears, or brachydactyly (short fingers or toes). A third 
category of physical findings is minor, or normal, variants. 
While these findings may also represent medically insignificant 
departures from normal development, they occur at a low 
frequency among the normal general population. Examples 
include cafe-au-lait macules, single palmar creases, and fifth 
finger clinodactyly. It is important to appreciate that minor 
anomalies and variants are significant only when taken in 
context. For example, while preauricular ear pits are common 
in the general population, they may lead to the diagnosis of 
branchiootorenal syndrome when identified in a patient with 
sensorineural hearing loss and renal anomalies. 
Although major anomalies are more obvious and tend to 
draw attention to the patient more quickly, it is important to 
recognize that they are not more important than minor 
anomalies or normal variants as clues to a diagnosis. Rather, it 
is often the most subtle findings, discernable only through a 
genetics physical exam, that lead to the diagnosis of a genetic 
syndrome. Learning to differentiate a minor anomaly from 
normal variation is vitally important, as it is through these 
subtle anomalies that most genetic diagnoses are made. In 
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particular, the rarer physical features may be the most useful in 
arriving at the correct differential diagnosis. Descriptions of 
normal features and variations can be found in excellent texts 
such as Diagnostic Dysmorphology or Smith’s Recognizable 
Patterns of Human Malformation. 
Guidelines to performing the genetic physical exam 
The exam itself has two interrelated components: 
descriptive observation and careful measurement. Each 
physical feature should be evaluated, then normal and variant 
features should be accurately described using accepted standard   
terminology.   While   impressions are important (e. g., “the 
palpebral fissures look small”), they are insufficient alone. “No 
clinical judgment should ever be made on a measurable 
parameter without actually having measured and compared it to 
standard references” (Hall, 1993). For example, hypertelorism 
(widely spaced eyes) noted on casual observation may be an 
illusion caused by a widened nasal bridge or epicanthal folds; 
measuring interpupillary distance may reveal that eye spacing 
actually falls within the normal range. Distinguishing such 
differences may be of considerable importance when trying to 
determine if minor anomalies are present and consistent with a 
particular syndrome. 
In some cases, a genetic syndrome can be diagnosed by 
the overall appearance, or “gestalt” of the facial appearance. 
This ability to instantaneously recognize a syndrome is 
powerful and impressive to one’s colleagues. However, even 
an experienced dysmorphologist can be wrong if one is too 
quick to make a diagnosis as many findings are common to 
multiple disorders. Therefore, a careful and complete exam is 
warranted even in apparently obvious cases. Starting with the 
“big picture” is a useful approach, however, for examining 
each body region if followed by sequential evaluation of 
smaller component subunits within that region. 
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Components of the physical exam 
When examining the patient’s physical characteristics, 
it is important to be systematic and thorough. Growth 
parameters (i. e., head circumference, height, and weight) 
should be recorded on all patients including adults. The general 
appearance and behavior of a patient should also be carefully 
observed. Many genetic disorders have characteristic behavior 
that may have as much diagnostic importance as any physical 
finding.  
A useful regional approach is to start with examination 
of the head and proceed downward. Greatest attention is given 
to examination of the head and face, as this is where the 
greatest variability of human features is seen. Assessing 
symmetry, placement, and proportions both of overall 
appearance and of all paired structures (e. g., eyes and ears) 
may detect differences not otherwise appreciated. The skull 
should be observed for symmetry and contour, then palpated 
for ridging of sutures and fontanel sizes. The forehead should 
be evaluated for contour and breadth. The placement, rotation, 
size, and configuration of the ears should be noted, as well as 
the presence of preauricular pits or tags. The eye distances 
should be measured. The external eye should be evaluated for 
unusual position or structural abnormalities of the lids, irises, 
or pupils. Ophthalmologic evaluation for cataracts or retinal 
abnormalities should be examined. The nose should be 
evaluated for the configuration of the nasal bridge and tip, as 
well as symmetry of the nasal septum. The configuration of the 
philtrum should be noted, along with the size of the mouth and 
any unusual features of the lips. The arch of the palate should 
be observed, along with any cleft of the palate or uvula. Teeth 
should be evaluated for size, placement, and abnormalities of 
enamel or configuration. In addition, the profile should be 
assessed for prominence or recession of the forehead, eyes, 
midface, and chin. Any redundancy of nuchal skin should be 
noted. Finally, a description of hair, eyebrows, and eyelashes 
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should include assessment of texture, colour, thickness, and 
length. 
Evaluation of the trunk includes measuring relative 
proportions of upper and lower segment lengths (as divided at 
the symphysis pubis), sternal length, chest circumference, and 
internipple distance. The chest, clavicles, ribcage, and spine 
should be examined for deformity or abnormalities of contour. 
The positioning and form of the nipples and sternum should be 
observed. Any heart murmur, abdominal wall defect, or 
organomegaly should be noted. Sacral spinal defects such as 
hair tufts or pits should be noted. Examination of the genitalia 
should include assessment of proper proportions and 
positioning of structures, as well as Tanner stage. 
Careful examination of the extremities can also yield 
useful diagnostic clues. The relative proportions and symmetry 
of the various segments of each limb should be noted, as 
specific abnormalities may indicate a particular skeletal 
dysplasia. All joints should be assessed for contractures, 
abnormal angulation, or hypermobility. Examination of the 
hands and feet require careful consideration, as they offer a 
wide range of insight into early fetal development. 
Measurements should be made of total hand, palm, middle 
finger, and foot lengths. Fingers and toes should be assessed 
for placement, contractures, webbing, and spacing. The contour 
of the soles of the feet should be noted. Careful observation 
should also be given to the texture and configuration of 
fingernails and toenails. For example, subungual fibromas may 
be the presenting sign of tuberous sclerosis in a patient with 
mental retardation and seizures. 
The skin should be carefully examined in an effort to 
detect and describe any birthmarks or abnormalities in 
pigment, texture, elasticity, or wound healing. This may require 
using ultraviolet light in fair-skinned individuals. Observing 
dermatoglyphic patterns and skin creases is also important. 
Some conditions have characteristic dermatoglyphic patterns, 
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as  exemplified  by a predominance of fingertip whorls in 
Smith – Lemli – Opitz syndrome. More generally, abnormal 
skin creases reflect an abnormality in early fetal movement 
before 18 weeks’ gestation. 
Placing the physical exam in context 
Information obtained from a detailed medical and 
family history will often guide the physical exam, allowing one 
to focus extra attention on specific findings. For example, a 
postpubertal male referred for evaluation of mental retardation 
should  be  assessed  for  large   ear  size and macroorchidism, 
i. e. features that would raise suspicion for fragile X syndrome. 
Similarly, using background knowledge will allow one to 
direct attention to features that may have been missed. For 
example, the examination of an infant with ambiguous 
genitalia  should   include   careful   analysis   of   the    toes,  
as cutaneous syndactyly (webbing) between the second and 
third toes in this context would raise suspicion for Smith –
Lemli – Opitz syndrome. 
Examining a patient’s family members and/or 
reviewing their photographs can establish the background 
features that may assist the examiner in understanding where 
their patient’s features might have originated. In particular, any 
parameter thought to be abnormal in the patient should be 
examined in their relatives. 
A final point to consider is that physical findings 
change with time in many genetic syndromes. In Prader – Willi 
syndrome, for example, affected newborns are hypotonic and 
manifest failure to thrive, but within several years they become 
hyperphagic and obese. Periodic evaluations are important in 
cases in which a diagnosis cannot be reached, as physical 
examination findings may have changed into a recognizable 
pattern consistent with a known diagnosis. Similarly, reviewing 
photographs of a patient at various ages may detect phenotypic 
features classic for a particular condition that are no longer 
recognizable. 
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2. MONOGENIC DISEASES 
 
Disorders caused by the inheritance of a single 
defective gene are known as monogenic diseases or single gene 
disorders.  
There are more than 6 000 known single-gene disorders 
which occur in 1:200 births.  
Some examples are cystic fibrosis, sickle cell anemia, 
Marfan syndrome, Huntington’s disease, hereditary 
hemochromatosis, Duchenne muscular dystrophy, hemophilia, 
sickle cell anemia and Tay – Sachs disease. 
The single-gene or monogenic diseases can be 
classified into three main categories: autosomal dominant, 
autosomal recessive, and X-linked.  
 
Marfan syndrome 
Marfan syndrome is an autosomal dominant disorder 
(25 % of cases are new mutations) affecting connective tissues 
caused by mutation in the gene encoding fibrillin 1 (FBN1). 
Fibrillin is the primary component of the microfibrils that 
allow tissues to stretch repeatedly without weakening. Because 
the patient’s fibrillin is abnormal, the connective tissues are 
looser than usual, which weakens or damages the support 
structures of the entire body. 
Antoine Marfan (1858–1942) first described it in 1896. 
Marfan syndrome affects three major organ systems of the 
body: the heart and circulatory system, the bones and muscles, 
and the eyes.  
The disorder has an incidence of at least 1 in 10 000. 
Signs and symptoms 
Features include: 
Musculoskeletal: 
– tall stature; 
– long limbs with significantly increased arm span and 
reduced upper to lower body segment ratio; 
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– long fingers (arachnodactyly); 
– joint laxity and flat feet; 
– long narrow face with deep set eyes; 
– high narrow palate and dental crowding; 
– kyphoscoliosis; 
– spondylolisthesis; 
– dural ectasia; 
– pectus excavatum (the patient’s breastbone or sternum is 
sunken inward); 
– pectus carinatum (the sternum is pushed outward and 
narrowed). A few patients may have a pectus excavatum on 
one side of their chest and a pectus carinatum on the other; 
– foot disorders (pes planus (flat feet) and chronic pain in 
feet); 
– protrusio acetabulae (the acetabuli becomes deeper than 
normal during growth). 
Cardiovascular:  
About 90 % of Marfan patients have cardiac complications. 
– mitral valve prolapse; 
– aortic enlargement; 
– aortic regurgitation; 
– infective endocarditis. 
Eye: 
– ectopia lentis (dislocation of the lens, often upward); 
– myopia (nearsightedness); 
– retinal detachment (untreated can cause blindness); 
– glaucoma; 
– cataracts. 
Other problems: 
– spontaneous pneumothorax; 
– obstructive sleep apnea;  
– emphysema; 
– striae (stretch marks of the skin). 
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Figure 1 – Marfan syndrome 
 
Diagnosis: 
– ultrasound (to try to determine the length of fetal 
limbs in at-risk pregnancies); 
– taking a family history; 
– examination of the patient’s eyes, heart, and bone 
structure.  
 
The examination should include: 
– echocardiogram taken by a cardiologist (only the 
echocardiogram can detect possible enlargement of the aorta); 
– slit-lamp eye examination by an ophthalmologist; 
– work-up of the patient’s spinal column by an 
orthopedic specialist.  
 
 
 22 
Treatment and management 
The treatment and management of Marfan syndrome is 
tailored to the specific symptoms of each patient.  
Cardiovascular system: 
– monitoring with an echocardiogram every six months 
until it is clear that the aorta is not growing larger. After that, 
echocardiogram once a year; 
– CT (computed tomography); 
– MRI (magnetic resonance imaging); 
– TEE (transesophageal echocardiogram). 
Medications: 
– beta-blockers propranolol (Inderal) and atenolol 
(Tenormin) to slow down the rate of aortic enlargement and 
decrease the risk of dissection by lowering the blood pressure 
and decreasing the forcefulness of the heartbeat; 
– patients who are allergic to beta-blockers may be 
given a calcium blocker such as verapamil; 
– prophylactic dose of an antibiotic (penicillin and 
amoxicillin) before having dental work or minor surgery.  
Surgical treatment.  
Surgery may be necessary if the width of the patient’s 
aorta  increases  rapidly  or  reaches  a  critical  size (about 2 in/ 
5 cm). The surgical treatment involves replacing the patient’s 
aortic valve and anticoagulant medication (warfarin). 
Musculoskeletal system 
Children should be checked for scoliosis by 
pediatricians at each annual physical examination and x rayed 
in order to measure the extent of scoliosis or kyphosis. 
Scoliosis between 20 
º
C and 40
 º
C in children is usually treated 
with a back brace. The child must wear this appliance about 23 
hours a day until growth is complete. If the spinal curvature 
increases to 40
º
 or 50
º
, the patient may require surgery. Surgical 
treatment of scoliosis involves straightening the spine with 
metal rods and fusing the vertebrae in the straightened position. 
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Spondylolisthesis is treated with a brace in mild cases. 
If the slippage is more than 30
º
, the slipped vertebra may 
require surgical realignment. 
Dural ectasia can be distinguished from other causes of 
back pain on an MRI. Mild cases are usually not treated. 
Medication or spinal shunting is used in severe cases to remove 
some of the spinal fluid. 
 
 
 
Figure 2 – Adult with Marfan syndrome 
 
Pectus excavatum and pectus carinatum can be treated 
by surgery. In pectus excavatum, the deformed breastbone and 
ribs are raised and straightened by a metal bar. After four to six 
months, the bar is removed in an outpatient procedure. 
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Figure 3 – Pectus excavatum 
 
Protrusio acetabuli may require surgery in adult life to 
provide the patient with an artificial hip joint if the arthritic 
pains are severe. 
Pain in the feet or limbs is usually treated with a mild 
analgesic (acetaminophen). Patients with Marfan syndrome 
should consider wearing shoes with low heels, special 
cushions, or orthotic inserts.  
Visual and dental concerns 
Patients with Marfan syndrome should have a thorough 
eye examination, including a slit-lamp examination to test for 
dislocation of the lens as well as nearsightedness. Dislocation 
can be treated by a combination of special glasses and daily use 
of 1 % atropine sulfate ophthalmic drops or by surgery. 
Glaucoma can be treated with medications or with surgery. 
Cataracts are treated with increasing success by implant 
surgery. All persons with Marfan syndrome should be taught to 
recognize the signs of retinal detachment (sudden blurring of 
vision in one eye becoming progressively worse without pain 
or redness). 
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Children with Marfan should be evaluated by dentist at 
each checkup for crowding of the teeth and possible 
misalignment, and referred to an orthodontist if necessary. 
People with Marfan syndrome should avoid sports or 
occupations that require heavy weight lifting, rough physical 
contact, or rapid changes in atmospheric pressure (e. g., scuba 
diving).  
Regular noncompetitive physical exercise, however, is 
beneficial for patients. Good choices include brisk walking, 
shooting baskets, and slow-paced tennis. 
 
Phenylketonuria 
Phenylketonuria (PKU) is an inherited, autosomal 
recessive disorder characterized by a deficiency in the enzyme 
phenylalanine hydroxylase (PAH). This enzyme is necessary to 
metabolize the amino acid phenylalanine to the amino acid 
tyrosine. The incidence of PKU is 1 in 15 000 births, but the 
incidence of this disease in Caucasian and Native American 
populations is higher than in African-American, Hispanic, and 
Asian populations. 
Signs and symptoms 
The affected infant is normal at birth. Mental 
retardation may develop gradually and may not be evident for 
the first few months. The IQ of PKU patients is generally lower 
than the IQ of their healthy peers. 
Other symptoms can include:  
– extreme patterns of behavior (hyperactive with 
purposeless movements, rhythmic rocking, and athetosis); 
– delayed speech development; 
– seizures (25 %) and electroencephalographic 
abnormalities (50 %); 
– characteristic body odor of phenylacetic acid which 
has been described as musty or mousy; 
– light body pigmentation (is due to a lack of melanin 
which normally colors the hair, skin, and eyes); 
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– vomiting; 
– seborrheic or eczematoid rash (is mild and disappears 
as the child grows older); 
– most infants are hypertonic with hyperactive deep 
tendon reflexes; 
– microcephaly; 
– prominent maxilla with widely spaced teeth; 
– enamel hypoplasia; 
– growth retardation.  
Diagnosis 
The primary diagnostic test for PKU is the 
measurement of phenylalanine levels in a drop of blood taken 
from the heel of a newborn baby’s foot (Guthrie test). In this 
test, PKU is confirmed by the appearance of bacteria growing 
around high concentrations of phenylalanine in the blood spot. 
Early diagnosis is critical. It ensures that the early 
treatment of PKU babies needs to develop normally and avoid 
the complications of PKU. 
 
 
 
Figure 4 – Neonatal screening for PKU 
 
PKU patients show high levels of phenylalanine and 
low levels of tyrosine in the blood. 
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Treatment 
Treatment for PKU is recommended for babies that 
show a blood phenylalanine level of 7–10 mg/dL or higher for 
more than a few consecutive days.  
Dietary therapy is the most common form of treatment 
for PKU patients. Phenylalanine is actually an essential amino 
acid. Diets provide very small amounts of phenylalanine and 
higher quantities of other amino acids, including tyrosine. The 
amount of allowable phenylalanine can be increased slightly as 
a child becomes older. PKU diets include all the nutrients 
normally required for good health and normal growth 
(carbohydrates, fats, vitamins, and minerals). High protein 
foods like meat, fish, chicken, eggs, nuts, beans, milk, and 
other dairy products are banned from PKU diets. Small 
amounts of protein foods (grains and potatoes) and low protein 
foods (some fruits and vegetables, low protein breads and 
pastas) are allowed. Sugar-free foods (diet soda, which 
contains the artificial sweetener aspartame) are also prohibited.  
Blood tests should be done in the early morning when 
phenylalanine levels are the highest. All patients with PKU 
should adhere to a strictly controlled diet for life. 
Kuvan (sapropterin dihydrocholoride) is the first drug 
which helps to manage PKU. The drug helps to reduce blood 
phenylalanine levels in individuals with PKU by increasing the 
activity of the PAH enzyme. Kuvan is effective only in 
individuals who have some PAH activity. Individuals who take 
this drug must continue to follow a phenylalanine-restricted 
diet and have blood tests to measure phenylalanine levels. 
PKU patients who receive early and consistent dietary 
therapy can develop fairly normal mental capacity to within 
about five IQ points of their healthy peers. By comparison, 
untreated PKU patients generally have IQ scores below 50. 
 Prognosis 
PKU is incurable, but early newborn screening, careful 
monitoring, and a life-long strict dietary management can 
 28 
prevent the development of serious mental incapacity and help 
PKU patients to live normal, healthy, and long lives. 
 
Homocystinuria 
The term homocystinuria is actually a description of a 
biochemical abnormality, although many consider 
homocystinuria to be a disease. Homocystinuria refers to 
elevated levels of homocysteine in the urine. This can be 
caused by different biochemical abnormalities and there are 
eight different gene changes that are known to cause excretion 
of too much homocysteine in the urine. The best known and 
most common cause of homocystinuria is the lack of 
cystathionine b-synthase (“classical homocystinuria” that is 
caused by cystathionine b-synthase deficiency (CBS 
deficiency)). 
Homocysteine is involved with the catabolism of 
methionine. Methionine is an essential amino acid. Methionine 
comes from dietary protein. Generally, the amount of 
methionine that is consumed is more than the body needs. 
Excess methionine is converted to homocysteine, which is then 
metabolized into cystathionine; cystathionine is then converted 
to cysteine. The cysteine is excreted in the urine. The 
conversion of homocysteine to cystathionine by cystathionine 
b-synthase requires vitamin B6 (pyridoxine). If cystathionine 
b-synthase is missing, then homocysteine cannot be broken 
down into cystathionine and cysteine, and instead, 
homocysteine is accumulated and the elevated levels of 
homocysteine and methionine can be found in the blood. 
Decreased levels of cysteine can be found in the blood. 
Elevated levels of homocysteine lead to a disease state that, if 
untreated, affects multiple systems, including the central 
nervous system, eyes, skeleton, and vascular system. 
Classical homocystinuria is an autosomal recessive 
condition. The worldwide frequency of individuals with CBS 
deficiency is 1 in 350 000. 
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Signs and symptoms: 
– tall and thin individuals with thinning and lengthening 
of the bones; 
– long, narrow face; 
– high arched palate (roof of the mouth); 
– long and thin fingers (arachnodactyly); 
– scoliosis; 
– pectus excavatum or pectus carinatum; 
– osteoporosis; 
– stiff joints; 
– dislocated lenses; 
– nearsightedness (myopia); 
– mental retardation or learning disabilities (untreated 
individuals); 
– psychiatric problems (depression, chronic behavior 
problems, chronic obsessive-compulsive disorder, and 
personality disorders). 
  The most frequent cause of death associated with CBS 
deficiency is blood clots that are formed in veins and arteries 
(thromboembolisms), pulmonary embolus and strokes. 
Complication of CBS deficiency is severe premature 
arteriosclerosis. 
Diagnosis: 
– CBS deficiency is diagnosed during the newborn 
screening (elevated level of methionine in blood). The 
screening is done by collecting blood from a pinprick on the 
baby’s heel prior to leaving the hospital, but at least 24 hours 
after birth. If the levels are elevated then follow-up testing to 
verify the diagnosis is performed. If not identified at newborn 
screening, the diagnosis is made by identifying low levels of 
cysteine in blood and urine; 
– measurements of the amount of methionine and 
homocysteine produced by lymphoblasts or fibroblasts can 
confirm the diagnosis of CBS deficiency; 
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– DNA testing is available for families in which a gene 
alteration is identified. The prenatal diagnosis by chorionic 
villus sampling (CVS) and amniocentesis is made.  
CBS deficiency has several features in common with 
Marfan syndrome. The dislocated lens in Marfan syndrome 
tends to be dislocated upward; the tendency for the lens 
dislocation is to be downward in CBS deficiency. Individuals 
who have Marfan syndrome tend to have congenital lens 
dislocation whereas individuals who have CBS deficiency have 
not been identified to have lens dislocation before 2 years of 
age. 
 
Cystic fibrosis 
Cystic fibrosis (also known as CF, mucoviscidosis) is 
an autosomal recessive inherited disease with high frequency in 
population (1:1000 – 1:3500 among newbornes). Frequency of 
heterozygote transmitters is 5 % and higher. Gene of 
mucoviscidosis is located in the 7
th
 chromosome and called the 
CFTR gene. There are over 500 known changes in the CFTR 
gene that can cause CF. However, 70 % of all people with an 
abnormal CFTR gene have the same defect, known as delta-
F508. The CFTR protein helps to produce mucus. Mucus is a 
complex mixture of salts, water, sugars, and proteins that 
cleanses, lubricates, and protects many passageways in the 
body (lungs and pancreas). Cystic fibrosis affects the body’s 
ability to move salt and water in and out of cells. This defect 
causes the lungs and pancreas to secrete thick mucus, blocking 
passageways and preventing function.  
CF primarily affects people of white northern European 
descent; rates are much lower in non-white populations. 
Signs and symptoms 
The most severe effects of cystic fibrosis are observed 
in the gastrointestinal (digestive) system, the respiratory tract, 
the sweat glands and male fertility. Symptoms develop 
gradually. 
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Basic forms of the disease are: 
– mixed, with affection of both gastrointestinal tract 
and respiratory system (75–80 %); 
– mainly pulmonary (15–20 %); 
– mainly intestinal (5 %). 
Gastrointestinal system: 
– meconium ileus. Babies who inherit CF have 
meconium ileus at birth (10–15 %). Meconium is the first dark 
stool that a baby passes after birth. The meconium of a 
newborn with meconium ileus is thickened, sticky. Meconium 
ileus causes abdominal swelling, vomiting and requires surgery 
immediately after birth; 
– abdominal symptoms are caused by the inability of 
the pancreas to supply digestive enzymes to the intestine. 
Undigested food passes into the large intestine. Bacterial action 
can cause gas and abdominal swelling. The large amount of fat 
remaining in the feces makes it bulky, oily, and foul-smelling; 
The person is ravenously hungry, underweight, and shorter 
than expected for his age. When CF is not treated, a child may 
develop symptoms of malnutrition (anemia, bloating and 
appetite loss); 
– diabetes (type I or insulin-dependent). Scarring of the 
pancreas destroys pancreatic cells which produce insulin; 
– fat within the liver. Complications of liver 
enlargement include internal hemorrhaging, ascites, spleen 
enlargement and liver failure; 
– other gastrointestinal symptoms can include a 
prolapsed rectum, intestinal obstruction and intussusception. 
Somewhat fewer than 10 % of people with CF do not 
have gastrointestinal symptoms.  
Respiratory tract 
– pansinusitis (is observed in X-ray); 
– nasal polyps, or growths (are not cancerous, do not 
require removal unless they become annoying); 
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– respiratory infection (bronchitis, bronchiolitis, 
pneumonia). The infecting organisms are the Staphylococcus 
aureus, Haemophilus influenzae and Pseudomonas aeruginosa. 
The fungus Aspergillus fumigatus may infect older children 
and adults. Lung infection is the major cause of death for 
people with CF; 
– emphysema; 
– recurrent respiratory infections lead to “digital 
clubbing,” in which the last joint of the fingers and toes 
becomes slightly enlarged. 
 
 
 
Figure 5 – Fingers of a patient with cystic fibrosis 
 
Sweat glands 
Sweat is much saltier than normal, and measuring the 
saltiness of a person’s sweat is the most important diagnostic 
test for CF. Older children and adults with CF compensate for 
this extra salt loss by eating more salty foods. Infants and 
young children are in danger of suffering its effects (heat 
prostration). Heat prostration is marked by lethargy, weakness, 
loss of appetite and should be treated as an emergency 
condition. 
Fertility 
98 % of men with CF are sterile, due to complete 
obstruction or absence of the vas deferens, the tube carrying 
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sperm out of the testes. Most women with CF are fertile. In 
both boys and girls puberty is delayed due to the effects of poor 
nutrition or chronic lung infection.  
Diagnosis: 
– clinical pictures (gastrointestinal or respiratory 
symptoms, salty sweat);  
– family  history of CF;  
– sweat test. It is both the easiest and the most accurate 
test for CF. A person with CF will have salt concentrations that 
are one-and-one-half to two times greater than normal. The test 
can be done for persons of any age, including newborns, and its 
results can be determined within an hour;  
– genetic testing. Genes from a small blood or tissue 
sample are analyzed for specific mutations; presence of two 
copies of the mutated gene confirms the diagnosis of CF in all 
but a very few cases. A negative gene test cannot rule out the 
possibility of CF. Amniocentesis;  
– newborn screening (IRT test). This is a blood test 
which measures the level of immunoreactive trypsinogen, 
which is generally higher in babies with CF than those without 
it. But there are many false positive results immediately after 
birth, that is why the second test is required in several weeks. 
The second positive result is usually followed by the sweat test. 
Treatment and management 
There is no cure for cystic fibrosis.  
Nutrition: 
– high-calorie diets;  
– vitamin supplements;  
– pancreatic enzymes to supplement or replace the 
inadequate secretions of the pancreas. Tablets containing 
pancreatic enzymes are taken with every meal. Because of 
incomplete absorption even with pancreatic enzymes, a person 
with CF needs to take in about 30 % more food;  
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– tube feeding for people with CF, who cannot absorb 
enough nutrients from the foods (nasogastric tube, gastro-
stomy tube or jejunostomy tube).  
Respiratory health: 
– lung function tests are done frequently (changes in 
functional lung volume and respiratory effort); 
– chest X-rays are taken once a year;  
– regular exercise;  
– clearing mucus from the lungs helps to prevent 
infection, and mucus control is an important aspect of CF 
management;  
– bronchial drainage (used to aid the mucociliary 
escalator). The person with CF lies on a tilted surface with 
head downward, alternately on the stomach, back, or side, 
depending on the section of lung to be drained. An assistant 
thumps the rib cage to help loosen the secretions;  
– drugs (bronchodilators can open up the airways, 
steroids reduce inflammation, and mucolytics loosen 
secretions);  
– antibiotics only during infection. Some antibiotics are 
given as aerosols directly into the lungs. Antibiotic treatment 
may be prolonged and aggressive; 
– supplemental oxygen;  
– lung transplantation. About 50 % of adults and more 
than 80 % of children who receive lung transplants live longer 
than two years.  
Alternative treatment 
Homeopathic medicine include: 
• mucolytics to help thin mucous; 
• supplementation of pancreatic enzymes to assist in 
digestion. 
• respiratory symptoms can be addressed to open lung 
passages. 
• hydrotherapy techniques to help ease the respiratory 
symptoms and help the body eliminate mucus; 
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• immune enhancements can help prevent the 
development of secondary infections; 
• dietary enhancements and adjustments are used to 
treat digestive and nutritional problems. 
Prognosis 
Early diagnosis is important to prevent malnutrition and 
infection from weakening the young child. People with CF may 
lead relatively normal lives. Although most men with CF are 
functionally sterile, new procedures for removing sperm from 
the testes are being tried, and may offer the chance to become 
fathers. Approximately half of people with CF live till the age 
of 30.  
 
Congenital hypothyroid syndrome 
Congenital hypothyroid syndrome is a condition in 
which a child is born with a deficiency in thyroid gland activity 
or thyroid hormone levels. The thyroid gland secretes thyroid 
hormones (thyroxine (T4) and triiodothyronine (T3)) into the 
bloodstream. A deficiency in the level of these hormones can 
affect the brain, heart, muscles, skeleton, digestive tract, 
kidneys, reproductive function, blood cells, other hormone 
systems, heat production, and energy metabolism. 
Other abnormalities can lead to congenital 
hypothyroidism including: 
• abnormal synthesis of thyroid hormones; 
• abnormal synthesis of thyroid-stimulating hormone 
(TSH) or thyrotropin-releasing hormone (TRH), which are 
regulatory hormones that affect the production of thyroid 
hormones; 
• abnormal response to thyroid hormones, TSH or TRH; 
• inadvertent administration of harmful drugs or 
substances to the pregnant mother, possibly resulting in 
temporary congenital hypothyroidism in the newborn; 
• dietary deficiency of iodine, a raw component vital to 
the manufacture of thyroid hormones. 
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Some abnormalities in thyroid hormone synthesis (TSH 
synthesis), or the response to TSH, are inherited in autosomal 
recessive fashion.  
Congenital hypothyroidism is twice as common in girls 
as in boys. The condition is less common in African Americans 
and more common in Hispanics and Native Americans. 
Signs and symptoms 
The signs and symptoms of congenital hypothyroidism 
are difficult to observe because the mother passes along some 
of her thyroid hormones to the fetus during pregnancy.  
Features: 
– jaundice (yellow skin); 
– noisy breathing; 
– enlarged tongue; 
– feeding problems (constipation, sluggishness, 
sleepiness, cool hands and feet, failure to thrive); 
– other signs (protruding abdomen, slow pulse, 
enlarged heart, dry skin, delayed teething, coarse hair, 
myxedema (swelling of the face, hands, feet, and genitals)); 
– retardation in physical growth, mental development, 
and sexual maturation. 
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Figure 6 – Baby with congenital hypothyroidism 
 
Diagnosis 
– screening test is performed during a newborn’s first 
few days of life. A sample of the child’s blood is analyzed for 
levels of thyroxine (T4), thyroid-stimulating hormone (TSH), 
or both, also require a second round of screening performed 
one to four weeks later. Once the diagnosis of congenital 
hypothyroidism is made, other tests can pinpoint the nature of 
the abnormality;  
– X-rays of the hip, shoulder, or skull often reveal 
characteristically abnormal patterns of bone development;  
 38 
– scintigraphy is a method by which images of the 
thyroid gland and any ectopic thyroid tissue are obtained to 
determine if the thyroid is absent or ectopic.  
Treatment and management 
Early treatment offers a good probability of normal 
development. Treatment of congenital hypothyroidism requires 
replacement of deficient thyroid hormones with levothyroxine 
(oral tablet form of T4). There is no need to directly replace 
T3, since T4 is converted to T3 by the liver and kidney. Blood 
levels of T4 should be checked regularly to ensure appropriate 
replacement. The blood levels of TSH should also be 
monitored since TSH is an indicator of the effectiveness of T4 
replacement.  
Prognosis 
If congenital hypothyroidism is detected and treated 
early in life, the prognosis is quite good. Most children will 
develop normally. The most severely affected infants may have 
mild mental retardation, speech difficulty, hearing deficit, short 
attention span, or coordination problems. 
 
Neurofibromatosis 
Neurofibromatosis (NF), or von Recklinghausen 
disease, is a dominant disorder which causes development of 
multiple soft tumors (neurofibromas). These tumors occur 
under the skin and throughout the nervous system. Both forms 
of neurofibromatosis are caused by a defective gene. Two types 
of NF exist, NF-1 (90 % of all cases), and NF-2 (10 % of all 
cases). NF-1 occurs due to a defect on chromosome 17; NF-2 
results from a defect on chromosome 22.  
Neurofibromatosis-I occurs in about 1 of every 4 000 
births.  
Signs and symptoms 
Diagnostic criteria for NF1 
There are two or more of the following criteria: 
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• six or more cafe-au-lait macules (patches of tan or 
light brown skin): 
> 5 mm diameter before puberty; 
> 15 mm diameter after puberty; 
• two or more neurofibroma of any type (occur under 
the skin, located along nerves or within the gastrointestinal 
tract) or one plexiform neuroma. Neurofibromas are small and 
rubbery, and the skin overlying them may be somewhat purple 
in color; 
• freckling in the axillary or inguinal regions; 
• two or more Lisch nodules (tiny tumors) in the iris of 
the eye; 
• optic glioma; 
• skeletal deformities (scoliosis, pseudarthrosis, 
humpback or bowed legs); 
• the presence of NF-1 in a patient’s parent, child, or 
sibling. 
Complications of NF1: 
• plexiform neurofibromas; 
• congenital bowing of tibia and fibula due to 
pseudarthrosis; 
• optic glioma; 
• scoliosis; 
• hydrocephalus; 
• epilepsy; 
• hypertension; 
• nerve root compression by spinal neurofibromas; 
• malignancy (leukemia, rhabdomyosarcoma, pheo-
chromocytoma, Wilms’tumor); 
• learning disability. 
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Figure 7 – Multiple neurofibromas 
 
Multiple CLSs over the back. Note the dermal 
neurofibromas below the right scapula and right side of the 
lower back. 
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Figure 8 – Large plexiform neurofibroma adjacent  
to the left axilla 
 
Diagnostic criteria for NF2: 
• bilateral vestibular schwannomas – tumors along the 
acoustic nerve (loss of hearing, weakness of the muscles of the 
face, headache, dizziness, poor balance, and uncoordinated 
walking); 
• first degree relative with NF2 and either: 
a) unilateral vestibular schwannoma; 
b) any two features listed below; 
• unilateral vestibular schwannoma and two or more 
other features listed below; 
• multiple meningiomas with one other feature listed 
below – meningioma, glioma, schwannoma, posterior sub-
capsular lenticular opacities, cerebral calcification. 
Cataracts frequently develop at an unusually early age. 
Diagnosis: 
– clinical signs, which can be detected by physical 
examination, ophthalmologic evaluation  and audiogram; 
– X-ray studies of the bones are frequently indicated to 
detect the development of deformities; 
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– CT scans and MRI scans are performed to track the 
development/progression of tumors in the brain and along the 
nerves; 
– auditory evoked potentials (the electric response 
evoked in the cerebral cortex by stimulation of the acoustic 
nerve) may be helpful to determine acoustic nerve 
involvement; 
– EEG (electroencephalogram) may be required for 
patients with suspected seizures; 
– regular blood pressure monitoring. 
 
 
 
Figure 9 – MRI showing the left optic nerve glioma  
with thickening of the nerve and proptosis 
 
Treatment 
There are no available treatments for the disorders 
which underlie either type of neurofibromatosis. Skin tumors 
can be surgically removed or treated with drugs 
(chemotherapy) or X-ray treatments (radiation therapy). 
Twisting or curving of the spine and bowed legs may require 
surgical treatment, or the wearing of a special brace. 
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Prognosis 
Prognosis varies depending on the tumor type which 
develops. As tumors grow, they begin to destroy surrounding 
nerves and structures. This destruction can result in blindness, 
deafness, increasingly poor balance, and increasing difficulty 
with the coordination. Deformities of the bones and spine can 
interfere with walking and movement. When cancers develop, 
prognosis worsens according to the specific type of cancer. 
 
Ehlers – Danlos syndrome 
The Ehlers – Danlos syndromes (EDS) is a group of 
genetic disorders that affect collagen structure and function.  
Collagen is a strong, fibrous protein that lends strength 
and elasticity to connective tissues (skin, tendons, organ walls, 
cartilage, and blood vessels). 
There are numerous types of EDS caused by changes in 
one of several genes. There are three patterns of inheritance for 
EDS: autosomal dominant, autosomal recessive, and X-linked 
(extremely rare). 
EDS  was  described  by Dr. Van Meekeren in 1682. 
Dr. Ehlers and Dr. Danlos further characterized the disease in 
1901 and 1908, respectively. Today one in 5000 to one in 
10000 people are affected by some form of EDS. 
Signs and symptoms 
Classification of EDS types was revised in 1997. The 
new classification involves categorizing the different forms of 
EDS into six major subtypes: 
– classical; 
– hypermobility; 
– vascular; 
– kyphoscoliosis; 
– arthrochalasia; 
– dermatosparaxis and collection of rare or poorly defined 
varieties.  
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Classical type 
Classical  type was divided into two separate types: 
type I and type II. EDS classical type is inherited in an 
autosomal dominant manner. 
Symptoms: 
– the skin has a smooth, velvety texture and bruises 
easily; 
– patients typically have extensive scarring, particularly 
at the knees, elbows, forehead, and chin; 
– joints are hyperextensible (tendency towards 
dislocation of the hip, shoulder, elbow, knee, or clavicle); 
– decreased muscle tone (delay in reaching motor 
milestones); 
– develop hernias or other organ shifts within the 
abdomen; 
– sprains and partial or complete joint dislocations. 
There are three major clinical diagnostic criteria for 
EDS classical type (skin hyperextensibility, unusually wide 
scars, joint hypermobility).  
 
 
 
Figure 10 – Ehlers – Danlos syndrome.  
Skin hyperextensibility 
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Hypermobility type (EDS type III): 
– excessively loose joints (large joints: elbows and 
knees; small joints (toes and fingers)); 
– partial and total joint dislocations (jaw, knee, 
shoulder); 
– many individuals experience chronic limb and joint 
pain (x rays of these joints appear normal); 
– the skin may also bruise easily; 
– osteoarthritis in adults; 
– is inherited in an autosomal dominant manner; 
– there are two major clinical diagnostic criteria: 
hyperextensible skin (or smooth and velvety skin) and 
generalized joint hypermobility. 
Vascular type (type IV) 
EDS vascular type is the most severe form and is 
inherited in an autosomal dominant manner. The connective 
tissue in the intestines, arteries, uterus, and other hollow organs 
may be unusually weak, leading to organ or blood vessels 
rupture (most likely between ages 20 and 40).  
Classic features: 
– individuals have large eyes, a thin pinched nose, thin 
lips, and a slim body; 
– skin is thin and translucent, with veins dramatically 
visible, particularly across the chest; 
– large joints have normal stability; 
– small joints in the hands and feet are loose and 
hyperextensibile; 
– other complications: skin bruises easily, collapsed 
lungs, premature aging of the skin on the hands and feet, 
ruptured arteries and veins; during and after pregnancy there is 
an increased risk of the arterial bleeding and rupture of uterus. 
Death usually occurs before the age of 50 years.   
EDS vascular type is caused by the change in the gene 
COL3A1, which codes for one of the collagen chains used to 
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build Collagen type III. Laboratory testing is available for this 
form of EDS. A skin biopsy may be used to demonstrate the 
structurally abnormal collagen. This type of biochemical test 
identifies more than 95 % of individuals with EDS vascular 
type. Laboratory testing is recommended for individuals with 
two or more of the major criteria. DNA analysis may be used 
to identify the change within the COL3A1 gene.  
Kyphoscoliosis type (type VI): 
– general joint looseness; 
– muscle tone is poor; 
– motor skill development is delayed; 
– infants have scoliosis; 
– eyes, skin and blood vessel are fragile and easily 
damaged. 
Kyphoscoliosis type is inherited in an autosomal 
recessive manner.  
This form of EDS is caused by the change in the PLOD 
gene on chromosome 1, which encodes the enzyme lysyl 
hydroxylase. A laboratory test is available in which urinary 
hydroxylysyl pryridinoline is measured. This test is extremely 
senstive and specific for EDS kyphoscolios type. Laboratory 
testing is recommended for infants with three or more of the 
major diagnostic criteria. 
Arthrochalasia type (type VIIB): 
– dislocation of the hip joint; 
– other joints are of unusually loose, leading to 
recurrent partial and total dislocations; 
– skin has a high degree of stretchability and bruises 
easily; 
– individuals may experience mildly diminished bone 
mass, scoliosis, and poor muscle tone. 
Arthrochalasia type is inherited in an autosomal 
dominant manner, and caused by the change in either of two 
components of Collagen type I, called proa1(I) type A and 
proa2 (I) type B. A skin biopsy may be performed to 
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demonstrate an abnormality in either component. Direct DNA 
testing is available.  
 
 
 
Figure 11 – Ehlers – Danlos syndrome. Dorsiflexion of all  
fingers is easy and absolutely painless 
 
Dermatosparaxis type (VIIC): 
– extremely fragile skin that bruises easily but does not 
scar excessively; 
– skin is soft and may sag, leading to an aged 
appearance even in young adults; 
– individuals may experience hernias. 
 Dermatosparaxis type is inherited in an autosomal 
recessive manner, is caused by the change in the enzyme called 
procollagen I N-terminal peptidase. A skin biopsy may be 
preformed for a definitive diagnosis of dermatosparaxis type. 
Other types 
There are several other forms of EDS that have not been 
as clearly defined as the aforementioned types: 
– soft, mildly stretchable skin; 
– shortened bones; 
– chronic diarrhea; 
– joint hypermobility and dislocation; 
– bladder rupture, or poor wound healing.  
Inheritance patterns within this group include X-linked 
recessive, autosomal dominant, and autosomal recessive. 
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Diagnosis: 
– clinical symptoms; 
– family history; 
– skin biopsies (for diagnosis of vascular, 
arthrochalasia, and dermatosparaxis types of EDS); 
– urine test (for the kyphoscoliosis type). 
Treatment and management 
Medical therapy relies on managing symptoms and 
trying to prevent further complications. There is no cure for 
EDS. Braces may be prescribed to stabilize joints, but surgery 
is necessary to repair joint damage caused by repeated 
dislocations. Physical therapy teaches individuals how to 
strengthen muscles around joints and may help to prevent or 
limit damage.  
Alternative treatment 
Large daily doses (1–4 g) of vitamin C may help 
decrease bruising and aid in wound healing. Therapy involves 
protecting the skin with sunscreen and avoiding activities that 
place stress on the joints. 
Prognosis 
The outlook for individuals with EDS depends on the 
type of EDS. Most individuals will have a normal lifespan. 
People with EDS vascular type, have an increased risk of fatal 
complications. People with EDS live with fears of significant 
and painful skin ruptures, of becoming pregnant, of their 
condition worsening, of becoming unemployed due to physical 
and emotional burdens, and of social stigmatization in general. 
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3. HEREDITARY DISEASES OF METABOLISM.  
MAIN PRINCIPLES OF TREATMENT  
OF METABOLIC DISORDERS 
 
Major categories of inherited metabolic diseases 
Traditionally the inherited metabolic diseases were 
categorized as disorders of carbohydrate metabolism, amino 
acid metabolism, organic acid metabolism, or lysosomal 
storage diseases. In recent decades, hundreds of new inherited 
disorders of metabolism have been discovered and the 
categories have proliferated. Following are some of the major 
classes of congenital metabolic diseases with prominent 
examples of each class. Many others do not fall into these 
categories. ICD-10 codes are provided where available. 
 1. Disorders of carbohydrate metabolism: 
o glycogen storage disease. 
 2. Disorders of amino acid metabolism: 
o phenylketonuria, maple syrup urine disease, 
glutaric acidemia type 1. 
 3. Disorders of organic acid metabolism 
(organic acidurias): 
o alcaptonuria. 
 4. Disorders of fatty acid oxidation and 
mitochondrial metabolism: 
o medium chain acyl dehydrogenase deficiency 
(glutaric acidemia type 2). 
 5. Disorders of porphyrin metabolism: 
o acute intermittent porphyria. 
 6. Disorders of purine or pyrimidine 
metabolism: 
o Lesch – Nyhan syndrome. 
 7. Disorders of steroid metabolism:  
o congenital adrenal hyperplasia. 
 8. Disorders of mitochondrial function:  
o Kearns – Sayre syndrome. 
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 9. Disorders of peroxisomal function: 
o Zellweger syndrome. 
 10. Lysosomal storage disorders:  
o Gaucher’s disease, Niemann Pick disease. 
Manifestations and presentations 
Because of the enormous number of these diseases and 
wide range of systems affected, nearly every “presenting 
complaint” to a doctor may have a congenital metabolic 
disease as a possible cause, especially in childhood. The 
following are examples of potential manifestations affecting 
each of the major organ systems: 
 growth failure, failure to thrive, weight loss; 
 ambiguous genitalia, delayed puberty, 
precocious puberty; 
 developmental delay, seizures, dementia, 
encephalopathy, stroke; 
 deafness, blindness, pain agnosia; 
 skin rash, abnormal pigmentation, lack of 
pigmentation, excessive hair growth, lumps and bumps; 
 dental abnormalities; 
 immunodeficiency, thrombocytopenia, anemia, 
enlarged spleen, enlarged lymph nodes; 
 many forms of cancer; 
 recurrent vomiting, diarrhea, abdominal pain; 
 excessive urination, renal failure, dehydration, 
edema; 
 hypotension, heart failure, enlarged heart, 
hypertension, myocardial infarction; 
 hepatomegaly, jaundice, liver failure; 
 unusual facial features, congenital 
malformations; 
 excessive breathing (hyperventilation), 
respiratory failure; 
 abnormal behavior, depression, psychosis; 
 joint pain, muscle weakness, cramps; 
 51 
 hypothyroidism, adrenal insufficiency, 
hypogonadism, diabetes mellitus. 
 
Diagnostic techniques 
Dozens of congenital metabolic diseases are now 
detectable by newborn screening tests, especially the expanded 
testing using mass spectrometry. This is an increasingly 
common way for the diagnosis to be made and sometimes 
results in earlier treatment and better outcome. There is a 
revolutionary GC/MS based technology with an integrated 
analytics system, which has now made it possible to test a 
newborn for over 100 genetic metabolic disorders. 
Because of the multiplicity of conditions, many 
different diagnostic tests are used for screening. An abnormal 
result is often followed by a subsequent “definitive test” to 
confirm the suspected diagnosis. 
Common screening tests used in the last sixty years: 
 ferric chloride test (turned colors in reaction to 
various abnormal metabolites in urine); 
 ninhydrin paper chromatography (detected 
abnormal amino acid patterns); 
 guthrie bacterial inhibition assay (detected a few 
amino acids in excessive amounts in blood) The dried blood 
spot can be used for multi-analyte testing using Tandem Mass 
Spectroscopy (MS/MS). This points to a disorder. The same 
has to be further confirmed by enzyme assays, GC/MS or DNA 
Testing; 
 quantitative measurement of amino acids in 
plasma and urine; 
 urine organic acid analysis by gas 
chromatography-mass spectrometry; 
 plasma acylcarnitines analysis by mass 
spectrometry; 
 urine purines and pyrimidines analysis by gas 
chromatography-massspectrometry. 
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Specific diagnostic tests (or focused screening for a 
small set of disorders): 
 tissue biopsy or necropsy: liver, muscle, brain, 
bone marrow; 
 skin biopsy and fibroblast cultivation for 
specific enzyme testing; 
 specific DNA testing. 
 
Disorders of carbohydrate metabolism 
Galactosemia is inherited by autosome-recessive type 
(classic and Duarte’s and Negro type). Frequency of 
galactosemia is from 1:18000 to 1:187000. Last studies data 
testifies that galactosemia is observed not less than inherited 
disorders of aminoacids metabolism. At galactosemia the 
absence or considerable disease of enzyme galactose 1-
phosphate-uridiltranspherase is observed, that leads to 
galactose and toxic galactose – 1 phosphate accumulation in 
blood and tissues. Increase of galactose amount is observed 
also in liquor and urine. Affection of liver, cerebrum, kidneys 
are observed, cataract, jaundice, hepatomegaly, dyspepsia 
develops, mental retardation is possible. 
For diagnostics of galactosemia the study of blood 
glucose level by enzyme method using glucoseoxydase or with 
the help of ortholuidinic reaction or probe on reduced 
substances in urine, microbiological test with mutant E Coli 
(DG-73) are used to specify the diagnosis. On the second stage 
carbohydrates chromanography on thin layer of silicogel, 
studying   of   galactose – 1 phosphat – uridiltransferase 
(by U. E. Veltishev), determination of galactose utilization by 
child’s erythrocytes (Tad’s method) is conducted. 
 
Hereditary fructose intolerance (HFI) or fructose 
poisoning is a hereditary condition caused by a deficiency of 
liver enzymes that metabolise fructose. It is also known as 
hereditary fructosemia.  
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At the core of the disease there is deficiency of fructose 
1–phosphate aldolase, which leads to fructose accumulations in 
blood and excretion with urine. 
In urine – albuminuria, hyperaminoaciduria, melituria. 
At older children hypoglycaemia conditions after eating fruits 
are possible (sharp paleness, weakness, sweating, arterial 
hypotension, vomiting, loss of consciousness, cramps, severe 
hypoglycaemia). 
Lactose intolerance is inherited metabolic pathology, 
conditioned by lactase insufficiency, at which an organism is 
unable to uptake lactose at all. Degradation of lactose in the 
intestine causes increasing of the osmotic pressure and diarrhea 
development.  
Disease symptoms show up from the first days of life 
because of milk eating. There develops: diarrhea, meteorism, 
hypotrophy and exicosis. 
Hydrogen breath test 
In a hydrogen breath test, overnight fasted, a dose of 
50 grams of lactose (in a water solution) is swallowed. If the 
lactose cannot be digested, enteric bacteria metabolize it and 
produce hydrogen. This, along with methane, can be detected 
in the patient’s breath by a clinical gas chromatograph or a 
compact solid state detector. The test takes about 2 to 3 hours. 
A medical condition with similar symptoms is fructose 
malabsorption. 
In conjunction, measuring the blood glucose level every 
10–15 minutes after ingestion will show a “flat curve” in 
individuals with lactose malabsorption, while the lactase 
persistent will have a significant “top”, with an elevation of 
typically 50 to 100 % within 1–2 hours. However, given the 
need for frequent blood draws, this approach has been largely 
supplanted by breath testing. 
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Stool acidity test 
This test can be used to diagnose lactose intolerance in 
infants, for whom other forms of testing are risky or 
impractical.  
Intestinal biopsy 
An intestinal biopsy can confirm lactase deficiency 
following discovery of elevated hydrogen in the hydrogen 
breath test. Modern techniques have enabled a test to be 
performed at the patient’s bedside which identifies the 
presence/absence of the lactase enzyme in conjunction with 
upper gastrointestinal endoscopy. However, for research 
applications such as mRNA measurements a specialist 
laboratory is required. 
Disorders of amino acid metabolism. Four types 
of amino acids metabolism disorders are distinguished: 
1) disorders accompanied by increase of their 
concentration in blood and urine (phenylketonuria, 
histidinemia, tyrosinosis); 
2) disorders accompanied by increase of their renal 
excretion without changes of blood level (homocystinuria); 
3) inherited disorders of transport of aminoacids 
(cystinuria); 
4) secondary hyperaminoacidurias as a result of tubular 
disorders. 
Histidinemia, also referred to as histidinuria, is a rare 
autosomal recessive metabolic disorder caused by a deficiency 
of the enzyme histidase. Histidase is needed for the metabolism 
of the amino acid histidine. 
The type of inheritance is autosomal recessive. 
Accumulating of histidine (norm is 2.12 mg/100 ml) and its 
derivates (imidazole pyruvate, imidazole acetate and imidazole 
lactate) and decrease of concentration of urocanine, glutamine 
and other acids takes place as a result of blockade. 
Histidinemia is characterized by increased levels of 
histidine, histamine and imidazole in blood, urine and 
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cerebrospinal fluid. This also results in decreased levels of the 
metabolite urocanic acid in blood, urine, and skin cells.
 
Tyrosinemia (or “Tyrosinaemia”) is an error of 
metabolism, usually inborn, in which the body cannot 
effectively break down the amino acid tyrosine. Symptoms 
include liver and kidney disturbances and mental retardation. 
Untreated, tyrosinemia can be fatal. 
Most inborn forms of tyrosinemia produce 
hypertyrosinemia (high levels of tyrosine). 
There are three types of tyrosinemia, each with 
distinctive symptoms and is caused by the deficiency of a 
different enzyme. 
At tyrosinosis, the change of parahydroxy-
phenylpyruvate to homogentisine acid is disordered. 
Tyrosinemia and tyrosinuria develop. 
Big quantity of parahydroxyphenyllactic acid, 
parahydroxyphenylpiruvate is excreted with urine. 
Type of inheritance is autosome-recessive. 
In blood the tyrosine level is increased and levels of 
other amino acids are a little decreased. 
 
Disorders of organic acid metabolism 
(Organic acidurias) 
Alkaptonuria (black urine disease or alcaptonuria) 
is a rare inherited genetic disorder of phenylalanine and 
tyrosine metabolism. This is an autosomal recessive condition 
that  is   due  to  a   defect   in  the  enzyme  homogentisate  
1.2-dioxygenase (EC 1.13.11.5) which participates in the 
degradation of tyrosine. As a result, a toxic tyrosine byproduct 
called homogentisic acid (or alkapton) accumulates in the 
blood and is excreted in urine in large amounts (hence – uria). 
Excessive homogentisic acid causes damage to cartilage 
(ochronosis, leading to osteoarthritis) and heart valves as well 
as precipitating kidney stones. 
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The diagnosis of alkaptonuria needs to be suspected 
before diagnostic testing can be performed using paper 
chromatography and thin layer chromatography. Both blood 
plasma and urine can be used for diagnosis. In healthy subjects, 
homogentisic acid is absent in both blood plasma and urine. In 
alkaptonuria, plasma levels are 6.6 micrograms/ml on average, 
and urine levels are on average 3.12 mmol/mmol of creatinine.  
 
Niemann – Pick disease 
Definition 
Niemann – Pick disease (NPD) is a disorder of fat 
metabolism that causes abnormalities of the skin, eyes, 
musculoskeletal system, nervous system, liver, and lymphoid 
organs. It is named for German pediatricians Albert Niemann 
(1880–1921) and Ludwig Pick (1898–1935). Six types of the 
disease have been identified (A, B, C, D, E and F). 
Description 
Niemann – Pick disease is inherited through an 
autosomal recessive trait. The different types of NPD are 
characterized by an abnormal accumulation of sphingomyelin. 
A sphingomyelin is any group of sphingolipids (consists of a 
lipid and a sphingosine) containing phosphorus. It occurs 
primarily in the tissue of the nervous system. 
Some characteristics of Niemann – Pick disease may be 
common for all types. Common symptoms include jaundice, 
hepatosplenomegaly (enlargement of the liver and spleen), 
physical and mental impairment, and feeding difficulties. 
Symptoms for most types of NPD (A, B, C and D) are seen in 
infancy or early childhood. Alternate names associated with the 
NPD disorder are lipid histiocytosis, sphingomyelin lipidosis, 
and sphingomyelinase deficiency. 
Genetic profile 
Niemann – Pick disease is caused by an autosomal 
recessive genetic trait, therefore the condition will not appear 
unless a person receives the same defective gene for fat 
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metabolism from each parent. This means that if a person is 
heterozygous for the trait then he/she will be a carrier and if 
they are homozygous then they will show the trait. There is a 
25 % chance for each pregnancy that the disorder will be 
passed onto the child (ren) if both parents are heterozygous for 
the trait and a 100 % chance if both parents are homozygous 
for the trait. 
The gene for Niemann – Pick disease types A and B has 
been located on the short arm (p) of chromosome 11. The gene 
for types C and D has been located on chromosome 18. NPD 
types C and D are believed to be allelic disorders. This term 
means   that  the  two  types  are  due  to  different  mutations  
(a change in building block sequences) of the same gene. Type 
E is similar to type C and may be a variant form. It is possible 
that type F is a mild form of type B but as of 2000 there is no 
supportive research. 
Demographics 
Niemann – Pick disease affects males and females 
equally and has been identified in all races. Type A is the most 
common form of the disease and is responsible for about 80 % 
of  NPD cases. 
Types A and B occur mainly in families of eastern 
European Jewish descent (Ashkenazi). It is estimated that one 
in 75 may be a carrier. Type B is also common in individuals 
from Tunisia, Morocco, and Algeria. Type C is more common 
in Spanish-Americans in southern New Mexico and Colorado. 
As of 2000, it is believed that over 300 people in the United 
States are affected with type C and an estimated one million 
worldwide. Type D occurs in French-Canadian descendents 
from Nova Scotia. Type F has been found to affect people of 
Spanish descent. As of 2000, it is not clear as to which 
populations are affected by type E. 
 
 
 
 58 
Signs and symptoms 
Type A 
This is the infantile or acute form of Niemann – Pick 
disease. Abnormal accumulation of sphingomyelin is seen in 
the developing fetus. Sphingomyelin accumulation could 
represent 2–5 % of the total body weight in individuals with 
type A. Symptoms may progress rapidly and include the 
following: 
• Hepatosplenomegaly. Enlargement of the liver and 
spleen is due to the low levels of the enzyme 
sphingomyelinase. This enzyme is required to breakdown 
sphingomyelin in the body. The decreased levels of this 
enzyme cause sphingomyelin content of the liver and spleen to 
be abnormally high. This occurs between the ages of 6 and 12 
months. Occurence of liver enlargement is seen more 
commonly than that of the spleen. 
• Musculoskeletal abnormalities. Degenerative 
muscle weakness and floppiness may occur due to a decline in 
motor and intellectual functioning. This is caused by increased 
accumulation of sphingomyelin in the nervous system. Seizures 
and muscular spasms may also occur. 
• Macula. Pigmentation in the tissue of the eyes may 
occur. Formation of cherry-red spots may be seen in 
approximately 50 % of patients diagnosed with NPD type A. 
This is not visible and can only be detected using special 
instrumentation. 
• Additional abnormalities. These include jaundice, 
fever, and gastrointestinal (GI) problems such as vomiting, 
diarrhea, and abdominal distention. 
Type B 
This is the chronic form of Niemann – Pick disease. 
Symptoms progress slowly and begin during infancy or early 
childhood. Like type A, type B occurs due to a deficiency of 
the enzyme sphingomyelinase. Neurological involvement is 
minimal and usually absent. Symptoms are as follows: 
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• Hepatosplenomegaly. Abnormal enlargement of the 
liver and spleen occur due to the accumulation of 
sphingomyelin. 
• Macula. The formation of cherry-red spots on the 
eyes may be seen in some affected individuals. 
• Additional abnormalities. These include a slow 
growth rate and increased incidence of respiratory infections. 
Type C 
This type of Niemann – Pick disease occurs due to the 
inability to breakdown cholesterol. This may lead to a 
secondary deficiency of acid sphingomyelinase. Studies have 
shown that there may be two types of NPD type C, NPC1 and 
NPC2. NPC2 is believed to be caused by a deficiency of HE1 
(human epididymis-1), which is a cholesterol-binding protein. 
NPD type C can occur at anytime between infancy and 
adulthood but is usually seen in children between the  ages of  
3 and 10. The progression of symptoms in NPD type C is slow 
and the loss of mental and motor function usually occur in 
early adulthood. Symptoms are as follows: 
• Hepatosplenomegaly. The liver and spleen may be 
moderately enlarged due to the inability to breakdown 
cholesterol. 
• Musculoskeletal. Psychomotor dysfunction, seizures, 
tremors, and spasticity of the muscles result due to excessive 
accumulation of cholesterol in the brain. An individual with 
NPD type C may also exhibit extreme muscle weakness due to 
emotional excitement and ataxia. Ataxia is the inability to 
coordinate voluntary muscle movements. 
• Eyes. Type C is characterized by vertical gaze palsy. 
This results in the difficulty or loss of up and down 
movement. Some individuals may experience opththalmoplegia 
(loss of muscle ability to move eyes). This is an impaired 
function of the muscles of the eyes and may cause the eyes to 
become stuck or fixed in an upward position. 
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• Additional abnormalities. These include dysarthria 
and jaundice. Dysarthria is the inability to form and speak 
words clearly. Jaundice is a yellow discoloration of the skin, 
eyes, and possibly the mucous membranes. 
Type D 
This is the Nova Scotia variant of Niemann – Pick 
disease. Like NPD type C, individuals with type D are unable 
to metabolize cholesterol properly. Individuals with type D do 
not suffer from a deficiency of acid sphingomyelinase. The 
symptoms of type D are very similar to type C but vary from 
case to case. 
Type E 
As of 2000, many researchers consider this to be a 
variant form of type C. NPD type E does not usually begin 
until adulthood and neurological impairment is rare. Symptoms 
include the following: 
• Hepatosplenomegaly. Enlargement of the liver and 
spleen may occur due to the accumulation of cholesterol. 
• Dementia. This is characterized by confusion, 
disorientation, deterioration of intellectual capacity and 
function, and impairment of the memory. Dementia is 
progressive and irreversible. 
• Ataxia. Individuals may have an inability to 
coordinate voluntary muscle movements. 
• Opththalmoplegia. Individuals with type E may have 
an inability to control the muscle movement of the eyes.This 
may cause the eyes to become stuck in a certain position. 
Type F 
This type of Niemann – Pick disease is characterized by 
finding of sea-coloured blue cells in the blood and/or bone 
marrow of individuals and therefore may be called sea-blue 
histocyte disease. It affects people of Spanish descent and may 
be a mild form of type B. Symptoms may include: 
• Hepatosplenomegaly. Abnormal enlargement of the 
liver and spleen may occur in individuals with NPD type F. 
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• Cirrhosis. The lobes of the liver may become covered 
with fibrous tissue (thickened tissue). This fibrous tissue 
obstructs blood flow through the liver. 
• Mild thrombocytopenia. Individuals with NPD type 
F may suffer from a decrease in the number of platelets found 
in the blood. Platelets are necessary for coagulation of the 
blood. 
• Macula. Pigmentation in the tissue of the eyes may 
occur. Individuals may develop a white ring around the 
maculae of the eyes. 
• Hair. Individuals may have an absence of hair in the 
axillary (armpit) area of the body. 
 
Diagnosis 
As of 2000, there is no objective diagnostic test for 
Niemann – Pick disease types D, E, and F. Types A and B are 
diagnosed through DNA testing or by a blood test. 
Blood tests for individuals with types A and B will 
show low levels of the enzyme sphingomyelinase in white 
blood cells and elevated sphingomyelin and free cholesterol. 
Type C can be diagnosed by prenatal testing of 
fibroclastic cells to determine their ability to process and store 
cholesterol. This is done by testing the amniotic fluid (liquid 
which bathes and cushions the fetus). Formation of foam cells 
occurs in all types of NPD and can be determined through a 
biopsy of bone marrow tissue. 
Diagnosis of all types is made possible by taking a 
detailed family history and a thorough examination of the 
individual. 
Symptoms of Niemann – Pick disease may be similar to 
those of Refsum syndrome (disorder of fat metabolism 
associated with abnormal accumulation of phytanic acid in the 
blood and other body tissues), Tay – Sachs disease (disorder 
found in Eastern European Jewish descendents that results in 
deterioration of the central nervous system), Sandhoff disease 
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(lipid storage disorder due to a deficiency of the enzyme 
hexosaminidase), Gaucher’s disease (lipid storage disease), and 
Sialidosis (metabolic disorder due to a deficiency of the 
enzyme alpha-neuraminidase). 
 
Treatment and management 
As of 2000, there is no specific treatment available for 
any type of Niemann – Pick disease. Individuals are treated on 
a symptomatic basis. As of 2000, individuals with NPD types 
A and B have not benefited from enzyme replacement 
therapies or organ transplants. Cholesterol lowering drugs and 
low cholesterol diets are often used for individuals with NPD 
types C and D. As of 2000, these have not been effective in 
slowing the progress of types C and D. 
Investigational therapies are being tested for types A, B, 
C and D. The possibility of treatment by bone marrow 
transplantation is being tested for types A and B. Studies have 
also been completed on the use of stem cell (a cell which 
produces usable tissues) transplantation as treatment for types 
A and B. Researchers at the National Institutes of Health are 
studying combinations of cholesterol lowering drugs for 
treatment of NPD types C and D. 
Social and lifestyle issues 
Individuals diagnosed with Niemann – Pick disease 
may want to seek counseling or attend support groups that 
focus on the psychological, physical, and social issues that may 
result due to the illness. 
Parents may want to seek counseling or attend support 
groups that focus on the lifestyle changes associated with 
having a child diagnosed with Niemann – Pick disease. 
Prognosis 
The prognosis for all types of Niemann – Pick disease 
varies. In type A, death usually results in early childhood. In 
individuals with types C and D, death usually results in 
adolescence or early adulthood. Individuals with type B have a 
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prolonged survival due to the decrease of neurological 
involvement. As of 2000, the prognosis for types E and F has 
not been adequately researched. Affected individuals and their 
families may want to seek genetic counseling. Pregnant women 
can receive prenatal testing for NPD type C. Pregnant women 
that are carriers and have a partner that is a carrier should 
receive genetic counseling regarding the 25 percent chance of 
the child having Niemann – Pick disease. Early diagnosis is 
important. Due to advances in medicine an early diagnosis may 
increase life expectancy. 
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4. GENERAL CHARACTERISTICS  
OF CHROMOSOMAL ANOMALIES  
(NUMERICAL AND STRUCTURAL).  
CLINICAL PICTURES OF MOST COMMON 
CHROMOSOMAL DISORDERS 
 
Chromosomal abnormalities are a group of conditions 
that are the result of a problem with one of the 23 pairs of 
chromosomes. Chromosomes are the structures within the 
body’s cells that contain genes. Normally, people have 23 pairs 
of chromosomes. For each of these pairs, one chromosome 
comes from the mother and the other chromosome comes from 
the father. However, an abnormality can affect any 
chromosome, including the sex chromosomes. 
A chromosomal abnormality can affect the number of 
chromosomes, the structure of certain chromosomes, or the 
composition of chromosomes. If the material found in 
chromosomes is balanced so that the expected amount is found 
in each cell, no abnormalities occur. If that balance is upset, 
chromosomal abnormalities occur and can cause a wide range 
of abnormalities, usually birth defects or death of the embryo 
or fetus before birth. 
Chromosome abnormalities usually occur when 
there is an error in cell division. There are two kinds of cell 
division. 
Mitosis results in two cells that are duplicates of the 
original cell. In other words, one cell with 46 chromosomes 
becomes two cells with 46 chromosomes each. This kind of 
cell division occurs throughout the body, except in the 
reproductive organs. This is how most of the cells that make up 
our body are made and replaced. 
   Meiosis results in cells with half the number of 
chromosomes, 23 instead of the normal 46. These are the eggs 
and sperm. 
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Figure 12 – Meiosis 
 
In both processes, the correct number of chromosomes 
is supposed to end up in the resulting cells. However, errors in 
cell division can result in cells with too few or too many copies 
of a chromosome. Errors can also occur when the 
chromosomes are being duplicated. 
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Other factors that can increase the risk of 
chromosome abnormalities are: 
Maternal Age. Women are born with all the eggs they 
will ever have. Therefore, when a woman is 30 years old, so 
are her eggs. Some researchers believe that errors can crop up 
in the eggs’genetic material as they age over time. Therefore, 
older women are more at risk of giving birth to babies with 
chromosome abnormalities than younger women. Since men 
produce new sperm throughout their life, paternal age does not 
increase risk of chromosome abnormalities. 
Environment. Although there is no conclusive 
evidence that specific environmental factors cause 
chromosome abnormalities, it is still a possibility that the 
environment may play a role in the occurence of genetic errors.   
 There are two types of chromosome 
abnormalities: abnormality of chromosome number or 
structure. 
 
Abnormalities of Chromosome Structure 
Deletions 
Deletions occur when a piece of a chromosome is 
missing. They may occur as a simple deletion or as a deletion 
with duplication of another chromosome segment. The latter is 
usually caused by a crossover in meiosis in a translocation 
carrier, resulting in an unbalanced reciprocal chromosomal 
translocation. Deletions may be located at the chromosome 
ends or in interstitial segments of the chromosome and are 
usually associated with mental retardation and malformations. 
Small telomeric deletions may be relatively common in 
nonspecific mental retardation with minor anomalies. The most 
commonly observed deletions in humans are  4p-, 5p-, 9p-, 
11p-, 13q-, 18p-, and 18q-, which are associated with well-
described. Deletions may be observed in routine chromosome 
preparations, but microdeletions are detectable only under the 
microscope with prophase chromosome studies. In 
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submicroscopic deletions, the missing piece can be detected 
only by using molecular probes or DNA studies. 
Microdeletions are defined as small chromosome 
deletions that are detectable only in high-quality 
(pro)metaphase preparations. These deletions often involve 
several genes so that the affected individual may be identified 
by an unusual phenotype associated with an apparent single 
gene mutation. Williams, Langer – Giedion, Prader – Willi, 
Angelman,     Rubinstein – Taybi,     Smith – Magenis,         
Miller – Dieker, Alagille, and velocardiofacial/DiGeorge 
syndromes have all been found to be associated with 
microdeletions. Submicroscopic deletions are not visible by 
microscopic examination and are detected only with specific 
probes for a DNA sequence or DNA studies. The deletion is 
recognized because of the absence of staining or fluorescence.  
 
Duplications 
Duplication is the presence of extra genetic material 
from the same chromosome. Duplications may result from the 
abnormal segregation in carriers of translocations or inversions. 
  
Inversions 
Inversions require the chromosome to break at two 
points. The broken piece is then inverted and joined into the 
same chromosome. Inversions have a frequency of 1/100 
liveborns and may be pericentric or paracentric. In pericentric 
inversions, the breaks are in the two opposite arms of the 
chromosome so that the intervening portion that contains the 
centromere is reversed. They are usually discovered because 
they change the position of the centromere. In contrast, 
paracentric inversions involve only chromosomal material from 
one arm of a chromosome. Carriers of inversions are usually 
normal, but they may have an increased risk of miscarriages 
and chromosomally abnormal offspring. 
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Figure 13 – The three major single chromosome mutations; 
deletion (1), duplication (2) and inversion (3) 
 
Translocations 
Translocations involve the transfer of chromosomal 
material from one chromosome to another. Translocations may 
be Robertsonian or reciprocal. They occur with a frequency of 
1/500 liveborn human infants. They may be inherited from a 
parent or appear de novo, with no other affected family 
members. 
Robertsonian translocations involve two acrocentric 
(centromere located at the end) chromosomes that fuse near the 
centromeric region with subsequent loss of the nonfunctional, 
very truncated short arms. The translocation chromosome is 
made up of the long arms of two fused chromosomes, hence 
the resulting count is only 45 chromosomes. The loss of the 
short arms of acrocentric chromosomes has no known 
deleterious effect. Although carriers of a Robertsonian 
translocation are usually phenotypically normal, they are at 
increased risk for miscarriages and abnormal offspring. 
Reciprocal translocations are the result of breaks in 
nonhomologous chromosomes with reciprocal exchange of the 
broken segments. Carriers of a reciprocal translocation are 
usually phenotypically normal but also have an increased risk 
 69 
of having chromosomally abnormal offspring and miscarriages 
because of abnormalities in the segregation of the 
chromosomes in the germ cells. 
 
Insertions 
Insertions occur when a piece of chromosome breaks at 
two points and is incorporated into a break in another part of a 
chromosome. This requires three breakpoints and may occur 
between two chromosomes or within one. 
 
 
Figure 14 – The two major two chromosome mutations; 
insertion (1) and translocation (2) 
 
Abnormalities of Chromosome Number 
Aneuploidy and Polyploidy 
When a human cell has 23 chromosomes, it is referred 
to as a haploid cell (the number of chromosomes in an ova or 
sperm). Any number of chromosomes that is an exact multiple 
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of the haploid number (e. g., 46, 69, 92 in humans) is referred 
to as euploid. Euploid cells with more than the normal diploid 
number of 46 chromosomes are called polyploid cells. 
Polyploid conceptions are usually not viable. However, they 
may be present in mosaic (more than one cell line) forms, 
which allow survival. Cells with three sets of chromosomes are 
called triploid and are frequently seen in abortus material and 
occasionally in viable humans, usually in mosaic form. Cells 
deviating from the multiples of the haploid number are called 
aneuploid (i. e., not euploid), indicating a missing or extra 
chromosome. 
 
Trisomies 
The most common abnormalities of chromosome 
number (aneuploidy) are trisomies. These occur when there are 
three representatives of a particular chromosome instead of the 
usual two. Trisomies are usually the result of meiotic 
nondisjunction (failure of a chromosome pair to separate). 
Trisomy may be present in all cells or may occur in mosaic 
form. Most individuals with trisomies exhibit a consistent and 
specific phenotype depending on the chromosome involved. 
The most frequent trisomy in humans is trisomy 21 or Down 
syndrome. Trisomies of chromosome 18 and chromosome 13 
are also relatively common and are associated with a 
characteristic set of congenital anomalies and mental 
retardation. 
 
Trisomy 21 (Down syndrome)  
 Dr. John Langdon H. Down first described a cluster of 
mentally retarded patients in an England asylum in an essay, 
“Observations on an Ethnic Classification of Idiots” in 1866.  It 
was not until the 1950s that an extra 21
st
 chromosome was 
found to be responsible for what was to become known as 
Down syndrome. The incidence is 1 in 600–800 births. The 
sporadic form has a higher frequency with advanced maternal 
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age. In mothers less than 25 years of age, the risk is 1 in 2 000 
births and climbs to 1 in 20 births for mothers over age 40.  All 
patients with Down syndrome have three copies of 
chromosome 21. In 95 % of patients, there are 47 
chromosomes with trisomy of chromosome 21.  In about 5 %, 
there are 46 chromosomes, with an abnormally translocated 
21
st
 chromosome. Robertsonian translocations involve the 
transfer of chromosomal material from 21 to usual 
chromosome number 13, 14, or 15. The Down phenotype 
occurs when even a small, but critical piece of the long arm of 
chromosome 21 is trisomic. Carriers of a Robertsonian 
translocation are usually phenotypically normal, but are at 
increased risk for miscarriages and chromosomally abnormal 
children.  Another cause is a 21q/21q translocation. This is 
rare, but significant because a carrier parent only has one 21
st 
chromosome (the translocated chromosome with double 
genetic material).  When this chromosome is passed on, all of 
the offsprings will have trisomy 21. An example of this is a 
mother who had this translocation and had four children with 
Down syndrome.  Milder phenotypes may be seen when 
patients are mosaic for trisomy 21.  This happens when 
nondisjunction occurs early in embryonic development as a 
mitotic error. 
 
 
Figure 15 – Karyotype of a patient with Down syndrome 
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Figure 16 – Risk correlation between maternal age  
and having of babies with Down syndrome 
 
Affected patients have a characteristic facies including 
epicanthal folds, a flat nasal bridge, small mouth, protruding 
tongue with microcephaly and a flat occiput. Other features 
may include a high arched palate, a single palmar crease 
(Simian crease). The pupils may have light smudgy opaque 
Brushfield spots.  
 
 
 
Figure 17 – Baby with Down syndrome 
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At birth, patients are often hypotonic and have a higher 
incidence of other types of malformations. Cardiac anomalies 
are present in 33–50 % and include endocardial cushion defects 
and ventricular septal defects. Gastrointestinal anomalies can 
include duodenal atresia and Hirschsprung’s disease. Later in 
life, hypothyroidism and leukemia can occur, and there is an 
increased susceptibility to infections. Atlantooccipital 
instability may be present in a few patients and is a concern 
when intubating these patients. A pneumonic for remembering 
the major complications found in Down syndrome patients is 
using the word VALIDATE as follows: VSD, atlantooccipital 
instability, leukemia, immunodeficiency, duodenal atresia, 
Alzheimer’s disease, thyroid dysfunction, and endocardial 
cushion defects. 
 
Prenatal diagnosis 
 The risk of trisomy 21 is directly related to maternal 
age. 
 Patients who will be 35 years or older on their due 
date should be offered chorionic villus sampling or second-
trimester amniocentesis.  
 Women younger than 35 years should be offered 
maternal serum screening at 16 to 18 weeks of gestation. 
 The maternal serum markers used to screen for 
trisomy 21 are alpha-fetoprotein, unconjugated estriol and 
human chorionic gonadotropin.  
 The use of ultrasound to estimate gestational age 
improves the sensitivity and specificity of maternal serum 
screening. During the first trimester of the majority of 
pregnancies, it is possible to measure the size of the fluid area 
at the back of the fetus’s neck, known as the nuchal 
translucency or NT. The increasing size of the NT indicates a 
greater risk of the fetus having Down syndrome. 
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Figure 18 – Ultrasound examination of a fetus  
with Down syndrome 
 
 There is no treatment for the trisomy itself, so therapy is 
directed towards other complications present, such as cardiac 
and gastrointestinal anomalies, thyroid dysfunction, and 
infections. Their IQ is usually about 50–75, at best they 
function at a sixth grade level, and few are severely retarded.  
These children are placed in infant stimulation programs, 
enrolled in special education classes, and later given 
occupational training to help them become more independent 
and a functioning part of society. It is very important to counsel 
parents who have one child with Down syndrome about the 
risk of having a second affected child. The risk of recurrence is 
1 % in otherwise low risk moms and if the parent is not a 
translocation carrier.  Obstetric screening tests can identify 
some pregnancies at risk, so that fetal chromosome testing can 
be offered.  Involvement in compassionate support groups 
should be encouraged to the parents. 
Trisomy 18 (Edwards Syndrome or Trisomy E)  
 Infants with trisomy 18 are severely affected and 
usually die in the first week of life. Less than 10 % of patients 
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survive beyond twelve months and are profoundly mentally 
retarded.  The cause of this syndrome is usually full trisomy for 
chromosome 18. The incidence is 1 in 4000–8000 births, with a 
3:1 predominance of affected females to males. The risk 
increases with maternal age. The recurrence risk is very low 
based on the observation that most affected children die in 
utero. Patients with trisomy 18 mosaicism have a less severe 
clinical expression and longer survival depending on the degree 
of mosaicism. Partial trisomy 18 varies in its clinical picture 
from mild mental deficiency and improved survival to being 
indistinguishable from full trisomy 18. This depends on the 
extent and which part of the chromosome is affected. 
 
 
 
Figure 19 – Karyorgam of a patient with trisomy 18  
(Edwards syndrome) 
  
Numerous malformations have been reported in trisomy 
18.  These infants have a characteristic head shape and facial 
features, such as a prominent occiput, low-set ears, and 
micrognathia. The hands are often clenched with the index 
finger overlapping the third finger. Dysmorphic joints produce 
this typical finger position. Deformities of the lower 
extremities include hypoplastic nails of the feet, malaligned 
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toes and “rocker-bottom feet”, where the calcaneus is 
prominent. Heart defects, such as ventricular septal defect, 
patent ductus arteriosus or atrial septal defect, are found in at 
least 50 % of these patients. They also have a short sternum 
with small nipples. 
 
 
 
Figure 20 –Trisomy 18 (Edwards Syndrome) 
 
 Supportive care is the treatment for this syndrome.  
Genetic counseling is indicated.  Chromosomal studies should 
be done to determine translocation cases.  The recurrence risk 
for full 18 trisomy cases is less than 1 % because most die in 
embryonic or fetal life. Some children with trisomy 18 have 
reached adulthood.  Heart failure or pneumonia are some of the 
complications that often cause death. 
 
Trisomy 13 (Patau Syndrome or Trisomy D) 
 The constellation of findings in this condition has been 
described as far back as the 1600s.  Klaus Patau and his 
colleagues were the first to attribute the syndrome of trisomy 
for chromosome 13 by cytogenetic analysis in 1960.  The cause 
of this syndrome is usually trisomy for chromosome 13. Its 
overall incidence is 1 in 12 000 births, but the risk increases 
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with maternal age.  The recurrence rate is very low, except for 
the parent who has a balanced translocation. Patients with 
trisomy 13 mosaicism have been described and usually have a 
milder phenotype depending on the degree of mosaicism.   
 Patients are severely affected and often die in infancy. 
The median survival has been reported as two and a half days. 
Surviving infants have severe mental retardation and may have 
midline CNS defects, incomplete development of the forebrain, 
apneic episodes and EEG abnormalities. Bilateral cleft lip and 
palate are common.  Microcephaly, microphthalmia, and 
deafness may also be found.  Lethal cardiac anomalies are 
found in 80 % of patients, with VSD being the most common.  
PDA, ASD, dextroposition, and valvular abnormalities can also 
occur.  Disorders of the extremities may include a single 
palmar crease (Simian crease). Polydactyly, particularly of all 
extremities, strongly suggests trisomy 13. Overlap of the 
middle and ring fingers are seen.   
 
 
Figure 21 – Trisomy 13 (Patau syndrome) 
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 Treatment is supportive. Prevention by genetic 
counseling is indicated. Critical decisions in regards to 
extensive therapy and resuscitation measures in a severely 
affected infant must be decided at birth. Those affected usually 
die in infancy; very few live to become adults. Children who 
survive are severely retarded and are rarely able to suck. They 
fail to thrive and have seizures. 
 
Klinefelter Syndrome (47 XXY) 
 Harry Fitch Klinefelter worked with Dr. Fuller Albright 
in clinical endocrinology when he saw his first patient, who 
was a young man with small testes and gynecomastia.  During 
his fellowship, he encountered 8 other patients with similar 
findings and described Klinefelter syndrome in 1942.  
Klinefelter syndrome affects 1 in 1000 newborn boys and is 
caused by an extra X chromosome from meiotic 
nondisjunction.  The incidence is 1 % among the mentally 
retarded and 3 %  among  males seen at infertility clinics.  In 
54 % of the patients, the extra X chromosome comes from the 
mother and in the other 46 %, the extra X chromosome comes 
from the father.  Maternal age, but not paternal age is often 
advanced.  The most common chromosomal pattern is 
47,XXY. Others have mosaic patterns: 46,XY/47,XXY; 
46,XY/48,XXYY; or 46,XX/47,XXY.  
 
 
 
Figure 22 – Karyorgam of a patient  
with Klinefelter syndrome (47 XXY) 
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These patients tend to have milder phenotypes.  
Children with mosaicism have a better prognosis for fertility 
and virilization. In chromosome variants with multiple X 
chromosomes (XXXY and XXXXY), the clinical 
manifestations are much more severe. In general, the mental 
and physical abnormalities associated with Klinefelter 
syndrome worsen as the number of X chromosomes increase. 
 The characteristic findings of Klinefelter syndrome 
usually do not become apparent until after puberty. They have 
a eunuchoid habitus; usually tall, slim and underweight, with 
long legs.  One third have gynecomastia and they have less 
facial hair.  Their gonads are small and soft, and the phallus 
tends to be smaller than average.  The seminiferous tubules are 
atrophied because of excess gonadotropin. There is hyperplasia 
of the Leydig cells, producing azoospermia and infertility. 
Cryptorchidism may occur in some patients. Hypogonadism 
becomes recognized after puberty when the testicles fail to 
grow and develop normally.  This is usually the time when the 
diagnosis is suspected.  Pubertal development may be delayed.  
These patients tend to have learning and psychosocial 
problems.  They have normal to borderline IQ, with a mean IQ 
of 90.  In boys with mental retardation, learning disabilities or 
adjustment problems at school, Klinefelter syndrome should be 
a consideration.  Later in life, these individuals are at higher 
risk to develop diabetes mellitus.  There is also an increased 
incidence of cancer of the breast, varicose veins, and 
pulmonary disease. 
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Figure 23 – Patients with Klinefelter syndrome (47 XXY) 
 
 Chromosomal analysis should be done to confirm the 
diagnosis of Klinefelter syndrome.  In males younger than 10 
years of age, they have normal levels of FSH and LH and 
respond appropriately to GnRH and hCG.  In late adolescence, 
testosterone levels decrease, and gonadotropins increase.  In 
adults, urinary excretion of gonadotropins is high, with levels 
comparable to those seen in post menopausal women.  
Gynecomastia is a result of an elevated estradiol to testosterone 
ratio.  In the management of Klinefelter syndrome, testosterone 
replacement therapy should start at 11 to 12 years of age, if 
testosterone levels are deficient and gonadotropin levels 
become elevated.  With early recognition and diagnosis, 
treatment can be initiated to allow a more normal maturation 
for the affected male, but infertility cannot be reversed. 
  
Turner Syndrome (45X) 
 In 1938, a series of young women with failure of sexual 
maturation, short stature, and neck webbing were reported by 
Henry Turner.  He believed this was due to a defect in the 
anterior pituitary gland.  It was not until 1959, when the 
absence of the X chromosome was first described by Charles 
Ford.  The incidence is 1 in 2 500 live female births, 95 % of 
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45X fetuses die in utero.  About 50 % of patients apparently 
have the full monosomy 45,X, the others all have detectable 
mosaicism.  About 2/3 retain the maternal X and 1/3 have the 
paternal X.  Advanced maternal age is not a factor in this 
syndrome.  Only one X is normal and functioning; the other X 
is not present or is missing a part of its chromosome by 
structural  abnormality,  deletion  or translocation.  Mosaicism 
45,X/46,XX or 45,X/46,XX/47,XXX  may also  be  present.  
10 % of Turner mosaics have a Y chromosome, 45,X/46,XY is 
seen.  The presence of the Y chromosome increases the risk of 
gonadoblastoma.  Milder phenotypes are usually seen in those 
without the full monosomic karyotype. 
 The characteristic features include a triangular face, 
small mandible, prominent ears, webbed neck, low posterior 
hair line, shield chest with wide set nipples, cubitus valgus 
(increased carrying angle of the elbow), and short stature.  
Sometimes short stature may be the only clinical finding 
present in a young girl.  Their average adult height is about 143 
cm (4 ft., 8 in.). In most of these girls, secondary sexual 
characteristics are absent.  
 
 
 
Figure 24 – Webbed neck of a patient with Turner 
syndrome  (45X) 
They have amenorrhea and are infertile due to ovarian 
dysgenesis. Intelligence is usually normal, but they may have a 
learning disability. These patients may have cardiac defects; 
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30–50 % have bicuspid aortic valve, and 10–20 % have 
coarctation of the aorta.  Other cardiac complications include 
aortic stenosis, aortic dissection and idiopathic hypertension. 
Urinary tract malformations are found with a higher frequency 
in these patients. Most common presentations include a 
horseshoe kidney, kidney located in the pelvis, double 
collecting system, or absence of a kidney.  
 
 
Figure 25 – Short stature. Tendency to become obese 
 
 Growth hormone alone or in combination with anabolic 
steroids has been successful in managing these patients.  This 
is still very controversial.  Opponents claim that growth 
hormone accelerates growth, but does not increase adult height.  
Therapy should begin when the height of the patient drops 
below the 5
th
 percentile on the growth curve.  For those who 
are deficient in estrogen and progestin, long term replacement 
therapy is required for development of secondary sexual 
characteristics and initiation of the menstrual cycle.  As for all 
post-menopausal women, these women especially need 
hormonal therapy, in combination with calcium 
supplementation and exercise, to help prevent osteoporosis. 
Rarely, spontaneous puberty and menses can occur and 
pregnancy is possible. There is an increased risk of giving birth 
to a child with chromosomal or congenital anomalies. Genetic 
counseling and a medical work up are required. Support groups 
can be of much benefit. These women can become independent 
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and lead productive lives. Most die in utero, but for those who 
survive, the average age of death is 69. Increased mortality can 
primarily be attributed to cardiovascular disease. 
 
Noonan Syndrome 
 This syndrome resembles Turner syndrome and occurs 
in males and females.  The occurrence is often sporadic, but an 
autosomal dominant inheritance has been reported.  A gene for 
this disorder has been mapped to chromosome 12q; although 
not in every family, suggesting that other loci may be involved.   
 The clinical manifestations are short stature, short or 
webbed neck, shield chest and pectus excavatum or carinatum.  
They have a characteristic facies; epicanthal folds, ptosis, 
hypertelorism, downslanting palpebral fissures, and low or 
abnormal ears.  Interestingly, their facies can normalize with 
age.  The most common cardiac abnormality is pulmonary 
valve stenosis, but they can also have atrial septal defects, left 
ventricular hypertrophy, or patent ductus arteriosus.  Males 
may have cryptorchidism, small penis, and hypogonadism.  
However, in males without cryptorchidism, fertility is normal.  
Fertility is also normal in females.  About 25 % of affected 
patients have some degree of mental deficiency.   
 There is no specific treatment.  Genetic counselling 
should be offered to parents regarding the recurrence risk. 
 
XYY Syndrome 
 In random newborn males, the incidence of the 47,XYY 
karyotype is 1 in 1000.  In some prison populations, the 
incidence is 1–2 %.  In institutionalized men or juvenile 
delinquents taller than 6 feet, 10 %  have XYY syndrome.  
Most 47XYY males are phenotypically normal, however 
variable, non-specific characteristics may be seen.  Stature 
tends to be tall, and patients may have large teeth and severe 
nodulocystic acne.  They are not well coordinated or strong 
relative to their large size.  Some males have anti-social 
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behavior.  They may be impulsive, hyperactive, have poor 
social skills, and low self esteem.  They were once stereotyped 
as being violent and aggressive.  However, longitudinal studies 
suggest that aggressive behavior is usually not a problem, and 
they learn to control their anger by the time they become young 
adults.  These males have a normal to low IQ, and 50 % have a 
learning disability.  The majority of patients are fertile.  Their 
sperm may have 23X, 23Y, 24XY or 24YY, so the syndrome 
can recur.  However, they usually have children with normal 
chromosomes. 
 XYY syndrome is diagnosed by karyotype.  There are 
no consistent clinical findings.  There is no treatment for this 
syndrome.  In general, affected children are normal.  However, 
behavioral modification is necessary in dealing with the 
hyperactivity and aggressiveness that may be seen during 
childhood.  The majority are well-adapted citizens. 
 
Fragile X Syndrome 
 The syndrome was first described by Martin and Bell in 
1943, though the fragile site on the X chromosome was 
reported in 1969 by Lubs.  It occurs in 1 in 1 000 males.  This 
disorder is caused by an expanded trinucleotide repeat (CGG) 
in the FMR-1 gene on the X chromosome with X-linked 
inheritance.  When cells, from patients with this disorder, are 
cultured in a certain medium deficient in folate or thymidine, 
the fragile site can be visualized.  The normal allele repeat 
range is 6–40. The intermediate allele repeat range is 41–60 
repeats (most are stably inherited), and the premutation allele 
repeat range is 61–200 repeats. Carriers of the premutation are 
usually phenotypically normal and not at increased risk for 
retardation. Females who carry this premutation may pass 
down an expanded version resulting in full expression of the 
phenotype in males and variable phenotypic expression in 
females.  The severity correlates with the increase in size of the 
repeat sequence.  The full mutation (disease causing) repeat 
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range is greater than 200 repeats.  Other disorders that are 
caused by expanded trinucleotide repeats include Huntington 
disease, myotonic dystrophy and Friedreich ataxia.  
 Physical abnormalities in males with fragile X 
syndrome include large ears, a large jaw and large, soft 
testicles. Connective tissue dysfunction, mitral valve prolapse 
and dental crowding can also be found.  Cluttered speech, 
autism, hyperactivity and mild to severe mental retardation are 
common.  Females with fragile X syndrome (usually 
heterozygous) tend to have a less severe clinical expression and 
only 1/3 have mental retardation.  
 
 
 
Figure 26 – Patient with Fragile X Syndrome 
  
Treatment and management includes supportive care.  
Genetic counselling is important in prenatal and postnatal 
diagnosis of fragile X syndrome.  Clinical expression is 
different depending on which parent transmits the gene.  DNA 
analysis helps to identify full mutations as well as premutation 
carriers.  The life expectancy is normal. 
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5. GENERAL CHARACTERISTICS 
OF MULTIFACTORIAL DISORDERS. 
PREVENTIVE METHODS 
 
Multifactorial inheritance 
 The concept of multifactorial inheritance implies that a 
disease is caused by the interaction of several adverse genetic 
and environmental factors. The liability of a population to a 
particular disease follows a normal distribution curve, most 
people showing only moderate susceptibility and remaining 
unaffected. Only when a certain threshold of liability is 
exceeded the disorder is manifested. Relatives of an affected 
person will show a shift in liability, with a greater proportion of 
them being beyond the threshold. Familial clustering of a 
particular disorder may therefore occur. Genetic susceptibility 
to common disorders is likely to be due to sequence variation 
in a number of genes, each of which has a small effect, unlike 
the pathogenic mutations seen in Mendelian disorders. These 
variations will also be seen in the general population and it is 
only in combination with other genetic variations that disease 
susceptibility becomes manifested. Unravelling the molecular 
genetics of the complex multifactorial diseases is much more 
dif ficult than for single gene disorders. Nevertheless, this is an 
important task as these diseases account for the great majority 
of morbidity and mortality in developed countries. Approaches 
to multifactorial disorders include the identification of disease 
associations  in  the  general  population,  linkage  analysis in 
affected families, and the study of animal models. 
Identification of genes causing the familial cases of diseases 
that are usually sporadic, such as Alzheimer disease and motor 
neurone disease, may give insights into the pathogenesis of the 
more common sporadic forms of the disease. In the future, 
understanding genetic susceptibility may enable screening for 
and prevention of common diseases as well as identifying 
people likely to respond to particular drug regimes. Several 
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common disorders thought to follow polygenic inheritance 
(such as diabetes, hypertension, congenital heart disease and 
Hirschsprung disease) have been found in some individuals and 
families to be due to single gene defects. In Hirschprung 
disease (aganglionic megacolon) family data on recurrence 
risks support the concept of sex-modified polygenic 
inheritance, although autosomal dominant inheritance with 
reduced penetrance has been suggested in some families with 
several affected members. Mutations in the ret protooncogene 
on chromosome 10q11.2 or in the endothelin-B receptor gene 
on chromosome 13q22 have been detected in both familial and 
sporadic cases, indicating that a proportion of cases are due to a 
single gene defect. 
 
 Risk of recurrence 
 The risk of recurrence for a multifactorial disorder within 
a family is generally low and mainly affects first degree 
relatives. In many conditions family studies have reported the 
rate with which relatives of the index case have been affected. 
This allows empirical values for risk of recurrence to be 
calculated, which can be used in genetic counselling. Risks are 
mainly increased for first degree relatives. Second degree 
relatives have a slight increase in risk only and third degree 
relatives usually have the same risk as the general population. 
The severity of the disorder and the number of affected 
individuals in the family also affect recurrence risk. The 
recurrence risk for bilateral cleft lip and palate is higher than 
the recurrence risk for cleft lip alone, and the recurrence risk 
for neural tube defect is 4 % after one affected child, but 12 % 
after two. Some conditions are more common in one sex than 
the other. In these disorders the risk of recurrence is higher if 
the disorder has affected the less frequently affected sex. As 
with the other examples, the greater genetic susceptibility in 
the index case confers a higher risk to relatives. A rational 
approach to preventing multifactorial disease is to modify 
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known environmental triggers in genetically susceptible 
subjects. Folic acid supplementation in pregnancies at 
increased risk of neural tube defects and modifying diet and 
smoking habits in coronary heart disease are examples of 
effective intervention, but this approach is not currently 
possible for many disorders. 
 
 Heritability 
 The heritability of a variable trait or disorder reflects the 
proportion of the variation that is due to genetic factors. The 
level of this genetic contribution to the aetiology of a disorder 
can be calculated from the disease incidence in the general 
population and that in relatives of an affected person. Disorders 
with a greater genetic contribution have higher heritability, and 
hence, higher risks of recurrence. 
 
Factors increasing risk to relatives in multifactorial 
disorders: 
• high heritability of disorder; 
• close relationship to index case; 
• multiple affected family members; 
• severe disease in index case; 
• index case being of sex not usually affected. 
 
Twins 
 Twins share a common intrauterine environment, but  
though monozygous twins are genetically identical with respect 
to their inherited nuclear DNA, dizygous twins are no more 
alike than any other pair of siblings, sharing, on average, half 
their genes. This provides the basis for studying twins to 
determine the genetic contribution in various disorders, by 
comparing the rates of concordance or discordance for a 
particular trait between pairs of monozygous and dizygous 
twins. The rate of concordance in monozygous twins is high 
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for disorders in which genetic predisposition plays a major part 
in the aetiology of the disease. 
 The phenotypic variability of genetic traits can be 
studied in monozygous twins, and the effect of a shared 
intrauterine environment may be studied in dizygous twins. 
Twins may be derived from a single egg (monozygous, 
identical) or two separate eggs (dizygous, fraternal). 
Examination of the placenta and membranes may help to 
distinguish between monozygous and dizygous twins but is not 
completely reliable. Monozygosity, resulting in twins of the 
same sex who look alike, can be confirmed by investigating 
inherited characteristics such as blood group markers or DNA 
polymorphisms (fingerprinting). 
Twinning 
Dizygous twins: 
• may be familial; 
• more common in black people than white Europeans. 
Monozygous twins: 
• seldom familial; 
• occur in 0.4 % of all pregnancies; 
• associated with twice the risk of congenital 
malformations as singleton or dizygous twin pregnancies. 
 
Diabetes 
 A genetic predisposition is well recognised in both type I 
insulin dependent diabetes (IDDM) and type II non-insulin 
dependent diabetes (NIDDM). Maturity onset diabetes of the 
young (MODY) is a specific form of non-insulin dependent 
diabetes that follows autosomal dominant inheritance and has 
been shown to be due to mutations in a number of different 
genes. Clinical diabetes or impaired glucose tolerance also 
occurs in several genetic syndromes, for example, 
haemochromatosis, Friedreich ataxia, and Wolfram syndrome 
(diabetes mellitus, optic atrophy, diabetes insipidus and 
deafness). Rarely, diabetes is caused by the secretion of an 
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abnormal insulin molecule. IDDM affects about 3 per 1 000 of 
the population in the UK and is a T cell dependent autoimmune 
disease. Genetic predisposition is important, but only 30 % of 
monozygous twins are concordant for the disease and this 
indicates that environmental factors (such as triggering viral 
infections) are also involved. About 60 % of the genetic 
susceptibility to IDDM is likely to be due to genes in the HLA 
region. The overall risk to siblings is about 6 %. This figure 
rises to 16 % for HLA identical siblings and falls to 1 % if they 
have no shared haplotype. An association with DR3 and DR4 
class II antigens is well documented, with 95 % of insulin 
dependent diabetics having one or both antigens, compared to 
50–60 % of the normal population. As most people with DR3 
or DR4 class II antigens do not develop diabetes, these 
antigens are unlikely to be the primary susceptibility 
determinants. Better definition of susceptible genotypes is 
becoming possible as subgroups of DR3 and DR4 serotypes are 
defined by molecular analysis.  
 For example, low risk HLA haplotypes that confer 
protection always have aspartic acid at position 57 of the 
DQB1 allele. High risk haplotypes have a different amino acid 
at this position and homozygosity for non-aspartic acid 
residues is found much more often in diabetics than in non-
diabetics. The second locus identified for IDDM was found to 
be close to the insulin gene on chromosome 11. Susceptibility 
is dependent on the length of a 14bp minisatellite repeat unit. 
Short repeats (26–63 repeat units) confer susceptibility, 
perhaps by influencing the expression of the insulin gene in the 
developing thymus. Subsequent mapping studies have 
identified a number of other possible IDDM susceptability loci 
throughout the genome, whose modes of action are not yet 
known. NIDDM is due to relative insulin deficiency and 
insulin resistance. There is a strong genetic predisposition 
although other factors such as obesity are important. 
Concordance in monozygotic twins is 40–100 % and the risk to 
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siblings may approach 40 % by the age of 80. Although the 
biochemical mechanisms underlying NIDDM are becoming 
better understood, the genetic causes remain obscure. In rare 
cases, insulin receptor gene mutations, mitochondrial DNA 
mutations or mild mutations in some of the MODY genes are 
thought to confer susceptability to NIDDM. 
 
Coronary heart disease 
 Environmental factors play a very important role in the 
aetiology of the coronary heart disease, and many risk factors 
have been identified, including high dietary fat intake, impaired 
glucose tolerance, raised blood pressure, obesity, smoking, lack 
of exercise and stress. A positive family history is also 
important. The risk to first degree relatives is increased to six 
times above that of the general population, indicating a 
considerable underlying genetic predisposition. Lipids play a 
key role, and coronary heart disease is associated with high 
LDL cholesterol, high ApoB (the major protein fraction of 
LDL), low HDL cholesterol and elevated Lp(a) lipoprotein 
levels. High circulating Lp(a) lipoprotein concentration has 
been suggested to have a population attributable risk of 28 % 
for myocardial infarction in men aged under 60. Other risk 
factors may include low activity of paraoxonase and increased 
levels of homocysteine and plasma fibrinogen. Lipoprotein 
abnormalities that increase the risk of heart disease may be 
secondary to dietary factors, but often follow multifactorial 
inheritance. About 60 % of the variability of plasma cholesterol 
is genetic in origin, influenced by allelic variation in many 
genes including those for ApoE, ApoB, ApoA1 and hepatic 
lipase that individually have a small effect. Familial 
hypercholesterolaemia (type II hyperlipoproteinaemia), on the 
other  hand,  is  dominantly inherited  and  may  account for 
10–20 % of all early coronary heart disease. One in 500 of the 
general population is estimated to be heterozygous for the 
mutant LDLR gene. The risk of coronary heart disease 
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increases with age in heterozygous subjects, who may also 
have xanthomas. Severe disease, often presenting in childhood, 
is seen in homozygous subjects. Familial aggregations of early 
coronary heart disease also occur in people without any 
detectable abnormality in lipid metabolism. Risks to other 
relatives will be high, and known environmental triggers 
should be avoided. Future molecular genetic studies may lead 
to more precise identification of subjects at high risk as 
potential candidate genes are identified. 
 
Schizophrenia and affective psychoses 
 A strong familial tendency is found in both schizophrenia 
and affective disorders. The importance of genetic rather than 
environmental factors has been shown by reports of a high 
incidence of schizophrenia in children of affected parents and 
concordance in monozygotic twins, even when they are 
adopted and reared apart from their natural relatives. The same 
is true of manic depression. Empirical values for lifetime risk 
of recurrence are available for counselling, and the burden of 
the disorders needs to be taken into account. Both polygenic 
and single major gene models have been proposed to explain 
genetic susceptibility. A search for linked biochemical or 
molecular markers in large families with many affected 
members has so far failed to identify any major susceptibility 
genes. 
 
Congenital malformations 
 Syndromes of multiple congenital abnormalities often 
have Mendelian, chromosomal or teratogenic causes, many of 
which can be identified by modern cytogenetic and DNA 
techniques. Some malformations are non-genetic, such as the 
amputations caused by amniotic bands after early rupture of the 
amnion. Most isolated congenital malformations, however, 
follow multifactorial inheritance and the risk of recurrence 
depends on the specific malformation, its severity and the 
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number of affected people in the family. Decisions to have 
further children will be influenced by the fact that the risk of 
recurrence is generally low and that surgery for many isolated 
congenital malformations is successful. Prenatal 
ultrasonography may identify abnormalities requiring 
emergency neonatal surgery or severe malformations that have 
a poor prognosis, but it usually gives reassurance about the 
normality of a subsequent pregnancy. 
 
Mental retardation or learning disability 
 Intelligence is a polygenic trait. Mild learning disability 
(intelligence quotient 50–70) represents the lower end of the 
normal distribution of intelligence and has a prevalence of 
about 3 %. The intelligence quotient of offspring is likely to lie 
around the mid-parental mean.  One or both parents of a child 
with mild learning disability often have similar disability 
themselves and may have other learning-disabled children. 
Intelligent parents who have one child with mild learning 
disability are less likely to have another similarly affected 
child. By contrast, the parents of a child with moderate or 
severe learning disability (intelligence quotient 50) are usually  
of normal intelligence. A specific cause is more likely when  
the retardation is severe and may include chromosomal 
abnormalities and genetic disorders. The risk of recurrence 
depends on the diagnosis but in severe non-specific retardation 
is about 3 % for siblings. A higher recurrence risk is observed 
after the birth of an affected male because some of these cases 
represent X linked disorders. Recurrence risks are also higher 
(about 15 %) if the parents are consanguineous, because of the 
increased likelihood of an autosomal recessive aetiology. The 
recurrence risk for any couple increases to 25 % after the birth 
of two affected children. 
 94 
6. GENETIC COUNSELLING 
 
Definition and aims of genetic counselling 
Genetic counselling is a communication process that 
deals with the human problems associated with the occurrence 
or risk of occurrence, of a genetic disorder in a family. Genetic 
counsellors are health care professionals with specialized 
training and experience in the areas of medical genetics and 
counselling. The process aims to help the individual or family 
to: 
understand: 
• the diagnosis, prognosis and available management; 
• the genetic basis and chance of recurrence; 
• the options available (including genetic testing); 
choose: 
• the course of action appropriate to their personal and 
family situation; 
adjust: 
• to the psychosocial impact of the genetic condition in 
the family. 
 
Types of genetic counselling 
Genetic counsellors work with people concerned about 
the risk of an inherited disease. These patients represent several 
different patient populations. 
Prenatal genetic counselling is provided to couples 
that have an increased risk for birth defects or inherited 
conditions and are expecting a child or planning a pregnancy.  
Pediatric genetic counselling is provided to families 
with children suspected of having a genetic disorder or with 
children previously diagnosed with a genetic disorder.  
Adult genetic counselling is provided to adults with 
clinical features of an inherited disease or a family history of 
an inherited disease.  
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Cancer genetic counselling is provided to those with a 
strong family history of certain types of cancer. 
Genetic diagnosis 
The role of clinical geneticists is to establish an 
accurate diagnosis on which to base counselling and then to 
provide information about prognosis and follow up, the risk of 
developing or transmitting the disorder, and the ways in which 
this may be prevented or ameliorated.  
When a child is born with birth defects, for example, 
the information needs to be gathered concerning parental age, 
maternal health, pregnancy complications, exposure to 
potential teratogens, fetal growth and movement, prenatal 
ultrasound scan findings, mode of delivery and previous 
pregnancy outcomes. 
Examination 
Thorough physical examination is required, but 
emphasis will be focused on relevant anatomical regions or 
body systems. A careful search should be made for both minor 
and major congenital abnormalities. Measurements of height, 
weight and head circumference are important and standard 
growth charts and tables are available for a number of specific 
conditions. In some cases, clinical geneticists will need to rely 
on the clinical findings of other specialists (ophthalmologists, 
neurologists and cardiologists) to complete the clinical 
evaluation of the patient. 
Investigations 
Investigation of affected individuals and family 
members may include conventional tests (x-rays, biochemical 
analysis) as well as cytogenetic and molecular genetic tests. A 
search for associated anomalies in children with chromosomal 
disorders often includes cranial, cardiac and renal imaging 
along with tests for other specific components of the particular 
syndrome (immune deficiency). 
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Genetic specialists 
Clinical geneticists are medical practitioners who 
undertake specialist training in this discipline. Their primary 
training is usually in paediatrics or adult internal medicine but 
can be in other areas (obstetrics and gynaecology). 
Areas that are covered by genetic specialist practice 
include: 
• dysmorphology; 
• prenatal counselling and testing; 
• neurogenetics; 
• cancer genetics; 
• bone dysplasias; 
• metabolic diseases. 
Indications for formal genetic counselling 
Anybody who suspects that there might be an increased 
risk of a genetic condition or producing a child with a genetic 
condition or birth defect may wish to receive formal genetic 
counselling. This includes: 
• individuals who  themselves have a genetic disorder 
(e. g. myotonic dystrophy); 
• couples who have had a stillbirth; 
• couples who have had a child with a birth defect; 
• couples who have had a child with mental retardation; 
• family history of any of the above; 
• family    history    of    known    genetic   disorders   
(e. g. Huntington disease, muscular dystrophy); 
• multiple miscarriages; 
• exposure to radiation or drugs during pregnancy; 
• advanced maternal age; 
• consanguinity; 
• chromosome translocations; 
• cancers. 
For appropriate genetic counselling, the following 
are essential: 
• diagnostic precision; 
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• knowledge of risk; 
• knowledge of burden; 
• knowledge of reproductive options; 
• knowledge of scientific advances; 
• counselling skills. 
Process of genetic counselling 
The genetic specialist needs to devote at least 1 hour in 
quiet surroundings to each family. 
Medical records and doctors’ reports are best obtained 
before undertaking counselling as this will make the 
consultation more efficient.  
Detailed histories or records of probands (the affected 
individual through whom a family with a genetic disorder is 
ascertained) need to be obtained. A pedigree is drawn with a 
minimum of three generations. This should include information 
about stillbirths, deaths and health problems.  
Probands and other members of the family are 
examined carefully and investigated as necessary.  
Collection of samples for DNA 
With advances in DNA technology it has become 
essential to store samples of DNA from family members with 
the condition in question who are likely to die, as well as 
relatives such as grandparents. This enables subsequent family 
members to benefit from advancing knowledge. Such samples 
can also be obtained at the time of postmortem if not collected 
earlier.  
Testing to confirm a clinical diagnosis 
When a genetic test is requested to confirm a clinical 
diagnosis in a child or adult, specialist genetic counselling may 
not be requested until after the test result. It is therefore the 
responsibility of the clinician offering the test to inform the 
patient (or the parents, if a child is being tested) before the test 
is undertaken, that the results may have genetic as well as 
clinical implications. For late onset conditions, it is crucial that 
samples sent for diagnostic testing are from patients already 
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symptomatic, as there are stringent counselling protocols for 
presymptomatic testing. 
Predictive testing 
Predictive (presymptomatic) testing is a test on an 
asymptomatic person that allows an individual to know 
whether or not he or she continues developing the condition in 
question. Not all genetic diseases show their effect 
immediately at birth or in early childhood. Although the gene 
mutation is present at birth, some diseases do not appear until 
adulthood. If a specific mutated gene responsible for a late-
onset disease has been identified, a person from an affected 
family can be tested before the symptoms appear. Predictive 
testing is mainly available for neurodegenerative diseases 
(Huntington disease, autosomal dominant spinocerebellar 
ataxia) and some cancers (familial breast/ovarian cancer, 
familial bowel cancer).  
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7. METHODS OF PRENATAL DIAGNOSIS 
Prenatal diagnosis 
Prenatal diagnosis or prenatal screening (note that 
prenatal diagnosis and prenatal screening refer to two different 
types of tests) is testing for diseases or conditions in a fetus or 
embryo before it is born. The aim is to detect birth defects such 
as neural tube defects, Down syndrome, chromosome 
abnormalities, genetic diseases and other conditions, such as 
spina bifida, cleft palate, Tay – Sachs disease, sickle cell 
anemia, thalassemia, cystic fibrosis, muscular dystrophy, and 
fragile X syndrome. Screening can also be used for prenatal 
sex discernment. Common testing procedures include 
amniocentesis, ultrasonography including nuchal translucency 
ultrasound, serum marker testing, or genetic screening. In some 
cases, the tests are administered to determine if the fetus should 
be aborted, though physicians and patients also find it useful to 
diagnose high-risk pregnancies early so that delivery can be 
scheduled in a tertiary care hospital where the baby can receive 
appropriate care. 
Fetal screening is also done to determine characteristics 
of generally not considered birth defects, and avail for sex 
selection, for example. The rise of designer babies and parental 
selection for specific traits raises a host of bioethical and legal 
issues that are expected to dominate reproductive rights debates 
in the 21
st
 century. 
Some screening tests performed on the woman are 
intended to detect traits or characteristics of the fetus. Others 
detect conditions in the woman that may have an adverse effect 
on the fetus, or that threaten the pregnancy. For example, 
abnormally low levels of the serum marker PAPP-A have been 
shown to correspond to an increased risk of pre-eclampsia, in 
which the mother’s high blood pressure can threaten the 
pregnancy, though many physicians find regular blood-
pressure monitoring to be more reliable. 
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Reasons for prenatal diagnosis 
There are three purposes of prenatal diagnosis:  
1. To enable timely medical or surgical treatment of a 
condition before or after birth. 
2. To give parents the chance to abort a fetus with the 
diagnosed condition. 
3. To give parents the chance to “prepare” 
psychologically, socially, financially, and medically for a baby 
with a health problem or disability, or for the likelihood of a 
stillbirth. 
Having this information in advance of the birth means 
that healthcare staff as well as parents can better prepare 
themselves for the delivery of a child with a health problem. 
For example, Down syndrome is associated with cardiac 
defects that may need intervention immediately upon birth. 
Many expectant parents would like to know the sex of 
their baby before birth. Methods include amniocentesis with 
karyotyping, and prenatal ultrasound. In some countries, health 
care providers are expected to withhold this information from 
parents, while in other countries they are expected to give this 
information. 
Qualifying risk factors 
Because of the miscarriage and fetal damage risks 
associated with amniocentesis and CVS procedures, many 
women prefer to first undergo screening so they can find out if 
the fetal risk of birth defects is high enough to justify the risks 
of invasive testing. Since screening tests yield a risk score 
which represents the chance that the baby has the birth defect, 
the most common threshold for high-risk is 1:270. A risk score 
of 1:300 would therefore be considered low-risk by many 
physicians. However, the trade-off between risk of birth defect 
and risk of complications from invasive testing is relative and 
subjective; some parents may decide that even a 1:1000 risk of 
birth defects warrants an invasive test while others wouldn’t 
opt for an invasive test even if they had a 1:10 risk score. 
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Indications for prenatal diagnosis 
 Women over the age of 35. Due to the well-known 
association of advanced maternal age with increased risk of 
having a baby with Down syndrome and other autosomal 
trisomy syndromes, advanced maternal age has been the most 
common indication to be considered for prenatal diagnosis. 
The age of 35 years and onward  at the expected date of 
delivery is usually considered as advanced maternal age to 
offer prenatal diagnosis by invasive methods (like 
amniocentesis and chorionic villus sampling). The reason to 
consider this age is probably the risk, at 35 years, of having a 
fetus with a chromosome abnormality is thought to be equal to 
the risk of miscarriage associated with amniocentesis (approx. 
1 in 250). 
 Previous child with a chromosome abnormality. 
Despite having the normal chromosomes themselves, the 
parents of a child with chromosomal aneuploidy are at 
increased risk of having chromosomal abnormality in a 
subsequent child. For example, a woman at 30 years of age 
with a previous child having Down syndrome has a recurrence 
risk for any chromosomal abnormality of about 1/100, 
compared to the age-related population risk of about 1/390. 
 Family history of a chromosome abnormality. Prenatal 
diagnosis for a couple is often indicated if there is a family 
history of chromosomal abnormality, most commonly Down 
syndrome. For most couples the risk is no greater than that for 
the general population. This is because most cases of trisomy 
21 or other chromosomal abnormality will have arisen as a 
result of non-disjunction rather than as a result of the familial 
chromosomal translocation or other rearrangements. 
 Presence of a structural chromosome abnormality in 
one of the parents. In such case, the type of chromosomal 
abnormality and sometimes the parent of origin determine the 
risk of having anomaly in a child. The greatest risk, 100 % for 
 102 
Down syndrome, occurs only if either parent has a 21q21q 
Robertsonian translocation or isochromosome. 
 Family history of a single-gene disorder. For a positive 
family history for a single gene disorder (or if prospective 
parents have already had an affected child or if one of the 
parents is affected) that bears a significant risk to an offspring 
(recurrence risk 25 % to 50 %), the prenatal diagnosis is 
strongly indicated. Prenatal diagnosis is generally carried out 
by either biochemical or DNA analysis for a large number of 
single-gene disorders. In case of a family history of an X-
linked disorder for which there is no specific prenatal 
diagnostic test, the parents of a boy affected with an X-linked 
disorder may use fetal sex determination to help them decide 
whether to continue or to terminate a subsequent pregnancy 
because of the high recurrent risk (25 %) associated with it.  
 Family history of a neural tube defect. Because of the 
high risk of having a child with a neural tube defect (NTD), the 
prenatal diagnosis is indicated for first-degree relatives (and 
often second-degree relatives) of patients with NTDs. 
Ultrasonographic examination of the fetus along with assay of 
maternal serum alpha fetoprotein (AFP) can be used as non-
invasive method (instead of invasive amniocentesis) of prenatal 
diagnosis to detect NTD. 
 Family history of other congenital structural 
abnormalities. In such cases, a careful evaluation of the 
pedigree is helpful to determine the risk associated with each 
pregnancy. If the risk to a pregnancy is increased, a detailed 
ultrasonographic examination looking for the specific structural 
abnormality can be offered at around 16–18 weeks’ gestation.  
 Abnormalities identified in pregnancy. Any 
abnormalities identified during pregnancy by prenatal 
diagnostic screening procedures, such as triple testing and fetal 
anomaly scanning, require invasive prenatal diagnostic 
methods like amniocentesis and chorionic villus sampling for 
further confirmation. 
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 Other high-risk factors. These include: parental 
consanguinity, as it is associated with an increased risk that a 
child will have a hereditary disorder or congenital anomaly. 
 A history of recurrent miscarriages or a previous 
unexplained stillbirth is also associated with an increased risk 
of the problem during future pregnancy. A history of three or 
more unexplained miscarriages requires parental chromosome 
analysis to exclude a chromosomal rearrangement such as a 
translocation or inversion. 
 Women who are pregnant with multiples (twins or 
more). 
There are multiple ways of classifying the methods 
available, including the invasiveness and the time performed. 
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  Table 1 – Methods of prenatal screening and diagnosis 
 
Invasiveness Test Comments Time 
1 2 3 4 
Non-invasive Fetal cells 
in maternal 
blood 
(FCMB) 
Based    on   enrichment of   fetal cells   which   circulate   
in maternal blood. Since fetal cells hold all the genetic information   
of   the  developing  fetus  they  can  be  used  to perform prenatal 
diagnosis 
First 
trimester 
Non-invasive Cell-free fetal 
DNA 
in maternal 
blood 
Based on DNA of fetal origin circulating in the maternal blood. 
Testing can potentially identify fetal aneuploidy and gender 
of a fetus as early as six weeks of pregnancy. Fetal DNA ranges 
from about  2–10 %  of  the  total  DNA  in maternal blood 
First 
trimester 
Non-invasive Preimplanta-
tion genetic 
diagnosis 
(PGD) 
During in vitro fertilization (IVF) procedures, it is possible 
to sample cells from human embryos prior the implantation. PGD 
is non-invasive itself, but IVF usually involves invasive 
procedures such as transvaginal oocyte retrieval 
Prior to 
implanta-
tion 
Non-invasive External 
examination 
Examination of the woman’s uterus from outside the body First or 
second 
trimester 
 
 
1
0
4
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Continuation of the table 1 
 
1 2 3 4 
Non-invasive Ultrasound 
detection 
Commonly dating scans (sometimes known as booking scans) 
from 7 weeks to confirm pregnancy dates and look for twins. 
The specialised nuchal scan at 11–13 weeks may be used to 
identify higher risks of Down syndrome. Later morphology scans 
from 18 weeks may check for any abnormal development 
First or 
second 
trimester 
Non-invasive Fetal heartbeat Listening to the fetal heartbeat First or 
second 
trimester 
Non-invasive Non-stress test Use of cardiotocography during the third trimester to monitor fetal 
wellbeing 
Third 
trimester 
Less invasive Transcervical 
retrieval 
of trophoblast 
cells 
Cervical mucus aspiration, cervical swabbing, and cervical 
or intrauterine lavage can be used to retrieve trophoblast cells 
for diagnostic purposes, including prenatal genetic analysis. 
Success rates for retrieving fetal trophoblast cells vary from 40 % 
to 90 %. It can be used for fetal sex determination and identify 
aneuploidies. Antibody markers have proven useful to select 
trophoblast cells for genetic analysis and to demonstrate that 
the abundance of recoverable trophoblast cells diminishes 
in abnormal gestations, such as in ectopic pregnancy 
or anembryonic gestation 
First 
trimester 
1
0
5
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Continuation of the table 1 
 
1 2 3 4 
Less invasive Maternal serum 
screening 
Including β-hCG, PAPP-A, alpha fetoprotein, inhibin-A First or 
second 
trimester 
More 
invasive 
Chorionic 
villus sampling 
Involves getting a sample of the chorionic villus and testing it. 
This can be done earlier than amniocentesis, but may have 
a higher risk of miscarriage, estimated at 1 %. 
After 10 
weeks 
More 
invasive 
Amniocentesis This can be done once enough amniotic fluid has developed 
to sample. Cells from the fetus will be floating in this fluid, 
and can be separated and tested. Miscarriage risk of amniocentesis 
is commonly quoted as 0.06 % (1:1600). By amniocentesis, 
it is also possible to cryopreserve amniotic stem cells 
After 15 
weeks 
More 
invasive 
Embryoscopy 
and fetoscopy 
Though rarely done, these involve putting a probe into a woman’s 
uterus to observe (with a video camera), or to sample blood 
or tissue from the embryo or fetus 
 
More 
invasive 
Percutaneous 
umbilical cord 
blood sampling 
PUBS is a diagnostic genetic test that examines blood 
from the fetal umbilical cord to detect fetal abnormalities 
24–34 
weeks 
1
06
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Maternal serum screening 
Maternal serum alpha-fetoprotein (MSAFP) 
Maternal Serum Alpha Fetoprotein (MSAFP) screening 
is non-invasive procedure in which the mother’s blood is taken 
and alpha-fetoprotein levels are measured. It is usually carried 
out during the 2
nd
 trimester and is used to detect abnormalities 
such as neural tube defects, more specifically anencephaly 
spina bifida, encephalocele, open ventral wall defects such as 
gastroschisis as well as Down’s syndrome. 
Alpha-Fetoprotein (AFP) is an embryo specific 
glycoprotein which is produced during the early stages of 
development by the liver, yolk sac as well as a small amount 
being produced by the gastrointestinal tract. AFP in adults is 
functionless as levels decrease drastically after birth with very 
low traces of AFP found in the average older adult with the 
only women experiencing spikes occurring in AFP levels 
during the onset of pregnancy, and it is in fact through the 
testing of the blood of pregnant women, that AFP levels can be 
measured. The function of AFP itself is unknown but due to its 
similarity to albumin it has been hypothesized that AFP could 
be a carrier protein or may even play a role in the metabolism 
of bilirubin or even may play a role in the control of female 
fertility through its anti-estrogenic actions. Furthermore, it has 
been observed that it does play a role in the embryonic and 
early fetal stages of development as fluctuating levels of AFP 
indicate the presence of abnormalities within a fetus.  
Ranges and Levels 
First Trimester:  
200–400 mg/dL. 
Second Trimester:  
14 weeks of gestation: 25.6 ng/ml; 
15 weeks of gestation: 29.9 ng/ml; 
16 weeks of gestation: 34.8 ng/ml; 
17 weeks of gestation: 40.6 ng/ml; 
18 weeks of gestation: 47.3 ng/ml; 
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19 weeks of gestation: 55.1 ng/ml;  
20 weeks of gestation: 64.3 ng/ml; 
21 weeks of gestation: 74.9 ng/ml.  
It should also be noted that “normal” values are around 
200 % higher in women with twin pregnancies. 
AFP in Pregnancy 
The highest maternal AFP concentration occurs in the 
mid third trimester of the pregnancy where the mean level is 
150–250 ng/ml. The concentration of AFP in maternal serum at 
any moment of gestation development seems to be related to 
the AFP level in the fetal circulation as well as in the placental 
size.  
Instances of abnormal AFP values can partly been 
explained by physiological deviations from the expected 
normal pregnancy e. g. in cases of under – or overestimated 
gestational age and multiple pregnancies. In other instances it 
has been found to indicate the presence of various fetal 
morphogenetic defects, such as open NTD (neural tube defect), 
hereditary congenital nephrosis (Finnish type), omphalocele, 
pilonidal sinus, esophageal atresia, and others.  
The maternal AFP level has often reported to be 
increased in pregnancies where the fetus has a neural tube 
defect.  
 
 
Figure 27 – Encephalocele 
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The optimal practical time for detecting open 
spinabifida by measuring materal serum AFP is at 16–18 
comepleted weeks of pregnancy. Because there is a certain 
degree of overlapping between the maternal AFP levels in 
pregnancies with and without fetal NTD, the AFP estimation in 
materal serum cannot per se serve as a specific diagnostic test, 
but it seems to be a useful screening test so as to select certain 
symptom-free women for further diagnostic procedures such as 
ultrasonography, amniocentesis, and amniography. 
Maternal Serum Alpha Protein as a Screening Test 
It should be made clear that MAFP is not a diagnostic 
test and is used only for screening purposes to determine the 
likelihood of a disease being present, with further testing 
always necessary for any sort of accurate diagnosis to take 
place. Furthermore, MAFP is a screening test that is carried out 
during the second trimester whereas other tests may be carried 
out during the first trimester and are more accurate. It is part of 
two tests, one called the Triple Screen Test which is a battery 
of tests that measure AFP levels as well as human chorionic 
gonadotropin (HCG) and unconjugated estriol uE3 and a 
second series of tests known as the Quadruple Screen Test that 
tests AFP, HCG, uE3 as well as Inhibin A which is a hormone 
that is released by the placenta. These tests also take into 
account age, ethnic background, weight as well as the baby’s 
gestational age. Currently, there are no known risks or side 
effects that have been associated with the MSAFP screening 
test except for any discomfort involved with the drawing of 
blood from the patient.  
When the maternal blood serum is being tested and has 
been collected the alpha fetoprotein undergoes an enzyme 
immunoassay procedure in order to determine the 
concentration of the protein in the blood. Firstly AFP is 
marked, usually with a colour or florescence marker, then the 
assay is placed in a spectrometer for a result on the 
concentration. Other less common procedures which are used 
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to determine the concentration of AFP are radio-immuno assay, 
bioluminescence and chemiluminescence methods. 
Maternal serum beta-HCG 
This test is most commonly used as a test for 
pregnancy. Beginning at about a week following conception 
and implantation of the developing embryo into the uterus, the 
trophoblast will produce enough detectable beta-HCG (the beta 
subunit of human chorionic gonadotropin) to diagnose 
pregnancy. Thus, by the time the first menstrual period is 
missed, the beta-HCG will virtually always be elevated enough 
to provide a positive pregnancy test. The beta-HCG can also be 
quantified in serum from maternal blood, and this can be useful 
early in pregnancy when threatened abortion or ectopic 
pregnancy is suspected, because the amount of beta-HCG will 
be lower than expected. 
Later in pregnancy, in the middle to late second 
trimester, the beta-HCG can be used in conjunction with the 
MSAFP to screen for chromosomal abnormalities, and Down 
syndrome in particular. An elevated beta-HCG coupled with a 
decreased MSAFP suggests Down syndrome. 
Very high levels of HCG suggest trophoblastic disease 
(molar pregnancy). The absence of a fetus on ultrasonography 
along with an elevated HCG suggests a hydatidiform mole. The 
HCG level can be used to follow up treatment for molar 
pregnancy to make sure that no trophoblastic disease, such as a 
choriocarcinoma, persists. 
Maternal serum estriol 
The amount of estriol in maternal serum is dependent 
upon a viable fetus, a properly functioning placenta, and 
maternal well-being. The substrate for estriol begins as 
dehydroepiandrosterone (DHEA) made by the fetal adrenal 
glands. This is further metabolized in the placenta to estriol. 
The estriol crosses to the maternal circulation and is excreted 
by the maternal kidney in urine or by the maternal liver in the 
bile. The measurement of serial estriol levels in the third 
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trimester will give an indication of general well-being of the 
fetus. If the estriol level drops, then the fetus is threatened and 
delivery may be necessary emergently. Estriol tends to be 
lower when Down syndrome is present and when there is 
adrenal hypoplasia with anencephaly. 
Inhibin-A 
Inhibin is secreted by the placenta and the corpus 
luteum. Inhibin-A can be measured in maternal serum. An 
increased level of inhibin-A is associated with an increased risk 
for trisomy 21. A high level of inhibin-A may be associated 
with a risk for preterm delivery. 
Pregnancy-associated plasma protein A (PAPP-A) 
Low levels of PAPP-A as measured in maternal serum 
during the first trimester may be associated with fetal 
chromosomal anomalies including trisomies 13, 18, and 21. In 
addition, low PAPP-A levels in the first trimester may predict 
an adverse pregnancy outcome, including a small for 
gestational age (SGA) baby or stillbirth. A high PAPP-A level 
may predict a large for gestational age (LGA) baby. 
 
Figure 28 – Screening strategies in the first and second 
trimester of pregnancy: “Triple” or “Quadruple” screen 
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The triple test is one of a range of screening tests that 
are used to identify a pregnant woman whose fetus is likely to 
be affected by trisomy 21 (Down syndrome) and who should 
then be offered a diagnostic test. All of the tests similar to the 
triple test are based on the same mathematical principle (Bayes 
theorem) and work by combining a prior probability derived 
from maternal age at expected date of delivery with a 
likelihood ratio usually based on two multivariate Gaussian 
distribution functions. 
This combination results in a reasonably accurate risk 
estimate of the probability that the fetus has Down syndrome. 
Women whose risk exceeds a specified cutoff are then offered 
a diagnostic test (i. e., amniocentesis or chorionic villus 
biopsy), which allows a cytogenetic diagnosis to be 
determined.  
The triple test is used only in the second trimester of 
pregnancy and now has a range of competitors. Combining the 
maternal serum assays may aid in increasing the sensitivity and 
specificity of detection for fetal abnormalities. The classic test 
is the Тtriple screen for alpha-fetoprotein (MSAFP), beta-
HCG,  and  estriol  (uE3). The “quadruple screen” adds 
inhibin-A. 
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Table 2 – Screening tests 
 
Test name Used in Analytes 
Double test Second 
trimester 
AFP + HCG (total or free-β) 
Triple test Second 
trimester 
As double test + unconjuga-
ted estriol 
Quadruple 
test 
Second 
trimester 
As triple test (using free-β 
HCG) + inhibin-A 
Combined 
test 
First trimester Ultrasound measurement of 
NT+ PAPP-A + free-β HCG 
Serum 
integrated 
test 
Both first and 
second trimester 
PAPP-A (first trimester) + 
quadruple test (or triple test) 
Integrated 
test 
Both first and 
second trimester 
As serum integrated test + 
NT in first trimester 
Contingent 
test 
Both first and 
second trimester 
Dependent on structure of 
contingent screen chosen 
Abbreviations: AFP – α-fetoprotein; HCG – human chorionic 
gonadotropin; NT – nuchal translucency; PAPP-A – 
pregnancy-associated plasma protein A 
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Ultrasound in prenatal diagnosis 
This is a non-invasive procedure that is harmless to 
both the fetus and the mother. High frequency sound waves are 
utilized to produce visible images from the pattern of the echos 
made by different tissues and organs, including the baby in the 
amniotic cavity. The developing embryo can first be visualized 
at about 6 weeks of gestation. Recognition of the major internal 
organs and extremities to determine if any are abnormal can 
best be accomplished between 16 to 20 weeks of gestation. 
Although an ultrasound examination can be quite useful 
to determine the size and position of the fetus, the size and 
position of the placenta, the amount of amniotic fluid, and the 
appearance of fetal anatomy, there are limitations to this 
procedure. Subtle abnormalities may not be detected until later 
in pregnancy, or may not be detected at all. A good example of 
this is Down syndrome (trisomy 21) where the morphologic 
abnormalities are often not marked, but only subtle, such as 
nuchal thickening. 
First trimester 
In the first trimester, ultrasound can be used to confirm 
the presence of an intra-uterine pregnancy, and determine its 
viability.  
 
 
Figure 30 – First trimester, ultrasound 
 115 
 
The crown-rump length measurement is used in dating 
until about 14 weeks, after which the biparietal diameter, head 
and abdominal circumferences, and femur length are used. 
Many of the major structural abnormalities can now be 
diagnosed at this stage in pregnancy. If the pregnancy is 
multiple, the number and chorionicity can be noted. Between 
10 and 14 weeks, the fluid at the back of the neck of the fetus 
can be measured (nuchal translucency). This is a useful 
screening test for predicting the likely risk of the fetus being 
affected by a chromosomal anomaly. If this test is unavailable, 
reliable dating by ultrasound is essential for biochemical 
screening for chromosomal abnormality, as the hormone levels 
vary with gestational age.  
Second trimester 
The second trimester ultrasound scan is usually done 
between 18 and 22 weeks of gestation. This involves a search 
for morphological abnormalities, including anomalies 
associated with chromosomal disorders (markers), and an 
assessment of fetal growth. Doppler ultrasound of the uterine 
arteries is performed between 20 and 24 weeks of gestation. 
Abnormal uterine artery Doppler waveform patterns are 
predictive of uteroplacental complications that may occur later 
in the pregnancy. 
Third trimester 
In the third trimester, or when the fetus becomes 
potentially viable, ultrasound can be used to monitor growth, or 
help in the diagnosis of fetal growth restriction. In addition to 
the growth of the fetus, ultrasound allows us to investigate its 
environment in utero, and determine the ability of the fetus to 
cope with adverse situations. Biophysical assessment, 
including liquor estimation and assessment of body and 
breathing movement, fetal heart rate analysis and umbilical 
artery with Doppler are accepted tests of wellbeing, performed 
throughout the world. Doppler assessment of the fetal 
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circulation provides more specific information regarding the 
fetal condition in-utero, but is not routinely available. 
The safety of ultrasound examinations during 
pregnancy has naturally been questioned. The consensus of 
opinion is that no detrimental effects of ultrasound use have 
been reported during pregnancy. At the levels of power and 
intensity currently used, there are numerous benefits derived 
but no known complications. 
Doppler fetal monitor 
Doppler fetal monitors provide information about the 
fetus similar to that provided by a fetal stethoscope. One 
advantage of the Doppler fetal monitor over a (purely acoustic) 
fetal stethoscope is the electronic audio output, which allows 
people other than the user to hear the heartbeat. One 
disadvantage is the greater complexity and cost and the lower 
reliability of an electronic device. 
Originally intended for use by health care professionals, 
this device is becoming popular for personal use. However, the 
FDA recommends against their home use, citing possible harm 
to a developing fetus and that these should only be used under 
the supervision of a healthcare professional when medically 
indicated for the benefit of the health of mother and child. 
Fetal heart rates 
Starting  at  week 5 the fetal heart rate accelerates by 
3.3 bpm per day for the next month. 
The fetal heart begins to beat at approximately the same 
rate as the mother’s, which is typically 80 to 85 bpm. The 
approximate fetal heart rate for weeks 5 to 9 (assuming a 
starting rate of 80) is as follows: 
– week 5 starts at 80 and ends at 103 bpm; 
– week 6 starts at 103 and ends at 126 bpm; 
– week 7 starts at 126 and ends at 149 bpm; 
– week 8 starts at 149 and ends at 172 bpm; 
– at week 9 the fetal heartbeat tends to beat within a 
range of 155 to 195 bpm. 
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At this point, the fetal heart rate begins to decrease, and 
generally falls within the range of 120 to 160 bpm by week 12. 
Nonstress test 
A nonstress test (NST) is a screening test used in 
pregnancy. The premise of the NST is that a well-oxygenated, 
non-acidemic fetus will spontaneously have temporary 
increases in the fetal heart rate (FHR). 
Interpretation 
 Reactive (normal) presence of two or more fetal heart 
rate accelerations within a 20-minute period, with or without 
fetal movement discernible by the woman. Accelerations are 
defined as 15 bpm above baselines for at least 15 seconds if 
beyond 32 weeks of gestation, or 10 bpm for at least 10 
seconds if at or below 32 weeks. 
 Nonreactive presence of less than two fetal heart rate 
accelerations within a 20-minute period over a 40-minute 
testing period. 
Vibroacoustic stimulation can wake the fetus, and is 
sometimes used to speed up the test or to facilitate further 
evaluation of a nonreactive nonstress test. 
Biophysical profile 
A biophysical profile is a prenatal ultrasound evaluation 
of fetal well-being involving a scoring system, with the score 
being termed Manning’s score. It is often done when a non-
stress test is non reactive, or for other obstetrical indications. 
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Table 3 – Biophysical profile 
 
Parameter Normal (2 points) Abnormal  
(0 points) 
NST/Reactive FHR At least two accelerations 
in 20 minutes 
Less than two 
accelerations 
to satisfy the test 
in 20 minutes 
US: Fetal breathing 
movements 
At least one episode of > 
30 s or > 20 s in 30 
minutes 
None  or  less  
than 30 s or 20 s 
US: Fetal activity/ 
gross body 
movements 
At least three or two 
movements of the torso 
or limbs 
Less than three 
or two 
movements 
US: Fetal muscle 
tone 
At least one episode 
of active bending and 
straightening of the limb 
or trunk 
No movements 
or movements 
are slow and 
incomplete 
US: Qualitative 
AFV/AFI 
At least one vertical 
pocket > 2 cm or more 
in the vertical axis 
Largest vertical 
pocket  2 cm 
 
Procedure 
The biophysical profile (BPP) has 5 components:  
4 ultrasound (US) assessments and a nonstress test (NST). The 
nonstress test evaluates fetal heart rate and response to fetal 
movement. The five discrete biophysical variables are: 
 fetal movement; 
 fetal tone; 
 fetal breathing; 
 amniotic fluid volume; 
 fetal heart rate. 
The “modified biophysical profile” consists of the 
nonstress test and amniotic fluid index only. 
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Interpretation 
Each assessment is graded either 0 or 2 points, and then 
added up to yield a number between 0 and 10. A BPP of 8 or 
10 is generally considered reassuring. A BPP normally is not 
performed before the second half of a pregnancy, since fetal 
breathing movements do not occur in the first half. 
The presence of these biophysical variables implies absence of 
significant central nervous system hypoxemia/acidemia at the 
time of testing. By comparison, a compromised fetus typically 
exhibits loss of accelerations of the fetal heart rate (FHR), 
decreased body movement and breathing, hypotonia, and, less 
acutely, decreased amniotic fluid volume. 
 
Table 4 – Recommended management based on the bio-
physical profile 
 
BPP Recommended management 
≤ 2 Labour induction 
4  Labour induction if gestational age > 32 weeks. 
  Repeating test same day if < 32 weeks, then 
delivery if BPP < 6. 
 Labor induction if > 36 weeks if favourable cervix 
and normal AFI. 
  Repeating test in 24 hours if < 36 weeks and 
cervix unfavourable; then delivery if BPP < 6, and 
follow-up if > 6 
8 Labour induction if presence of oligohydramnios 
 
Cardiotocography 
In medicine (obstetrics), cardiotocography (CTG) is a 
technical means of recording (-graphy) the fetal heartbeat 
(cardio-) and the uterine contractions (-toco) during pregnancy, 
typically in the third trimester. The machine used to perform 
the monitoring is called a cardiotocograph, more commonly 
known as an electronic fetal monitor (EFM). 
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External cardiotocography is used for continuous or 
intermittent monitoring. The fetal heart rate and the activity of 
the uterine muscle are detected by two transducers placed on 
the mother’s abdomen (one above the fetal heart and the other 
at the fundus). Doppler ultrasound provides the information 
which is recorded on a paper strip known as a cardiotocograph 
(CTG). 
Internal cardiotocography uses an electronic 
transducer connected directly to the fetal scalp. A wire 
electrode is attached to the fetal scalp through the cervical 
opening and is connected to the monitor. This type of electrode 
is sometimes called a spiral or scalp electrode. Internal 
monitoring provides a more accurate and consistent 
transmission of the fetal heart rate than external monitoring 
because factors such as movement do not affect it. Internal 
monitoring may be used when external monitoring of the fetal 
heart rate is inadequate, or closer surveillance is needed. 
 
 
Figure 31 – Schematic explanation of cardiotocography: 
heart rate (A) is calculated from fetal heart motion determined 
by ultrasound, and uterine contractions are measured 
by a tocodynamometer (B). These numbers are represented 
on a time scale with the help of a running piece of paper, 
producing a graphical representation 
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Interpretation of a CTG tracing requires both qualitative 
and quantitative description of: 
 uterine activity (contractions); 
 baseline fetal heart rate (FHR); 
 baseline FHR variability; 
 presence of accelerations; 
 periodic or episodic decelerations; 
 changes or trends of FHR patterns over time. 
 
 
 
Figure 32 – A typical CTG output for a woman 
not in labour. A – fetal heartbeat; B – indicator showing 
movements  felt  by  mother  (caused  by pressing a button); 
C – fetal movement; D – uterine contractions 
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Invasive methods of prenatal diagnosis 
There is a variety of invasive techniques available for 
prenatal diagnosis. Each of them can be applied only at  
specific time periods during pregnancy for the greatest utility. 
The invasive techniques employed for prenatal diagnosis 
include: 
 amniocentesis; 
 chorionic villus sampling; 
 cordocentesis; 
 fetoscopy. 
 
Figure 33 – Schema of pregnant uterus 
 
1. Embryo. 
2. Amniotic cavity. 
3. Chorion cavity. 
4. Uterine cavity. 
5. Chorion frondosum. 
A. Amniocentesis. 
B. Chorion biopsy through the abdominal wall. 
C. Umbilical blood sampling (V. umbilicalis). 
D. Transvaginal chorion biopsy 
 
Chorionic Villus Sampling (CVS) 
In this procedure, a catheter is passed via the vagina 
through the cervix and into the uterus to the developing 
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placenta under ultrasound guidance. Alternative approaches are 
transvaginal and transabdominal. The introduction of the 
catheter allows sampling of cells from the placental chorionic 
villi. These cells can then be analyzed by a variety of 
techniques. The most common test employed on cells, obtained 
by CVS, is chromosome analysis to determine the karyotype of 
the fetus. The cells can also be grown in culture for 
biochemical or molecular biologic analysis. CVS can be safely 
performed between 9.5 and 12.5 weeks of gestation. 
Indications 
Possible reasons for having a CVS can include: 
 abnormal first trimester screen results; 
 increased nuchal translucency or other abnormal 
ultrasound findings; 
 family history of a chromosomal abnormality or other 
genetic disorders; 
 parents are known carriers for a genetic disorder; 
 advanced maternal age (maternal age above 35). 
AMA is associated with an increased risk of Down’s syndrome 
and at age 35, the risk is 1:400. Screening tests are usually 
carried out first before deciding if CVS should be done. 
 
 
 
Figure 34 – A diagram of the technique  
of transvaginal chorionic villus sampling  
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CVS has the disadvantage of being an invasive 
procedure, and it has a small but significant rate of morbidity 
for the fetus; this loss rate is about 0.5 to 1 % higher than for 
women undergoing amniocentesis. Rarely, CVS can be 
associated with limb defects in the fetus. The possibility of 
maternal Rh sensitization is present. There is also the 
possibility that maternal blood cells in the developing placenta 
will be sampled instead of fetal cells and confound 
chromosome analysis. 
Amniocentesis  
Amniocentesis is a procedure used to diagnose fetal 
defects in the early second trimester of pregnancy. A sample of 
the amniotic fluid, which surrounds a fetus in the womb, is 
collected through a pregnant woman’s abdomen using a needle 
and syringe. Tests performed on fetal cells found in the sample 
can reveal the presence of many types of genetic disorders, 
thus allowing doctors and prospective parents to make 
important decisions about early treatment and intervention. 
Since the mid-1970s, amniocentesis has been used 
routinely to test for Down syndrome, by far the most common, 
nonhereditary, genetic birth defect, afflicting about one in 
every 1 000 babies. By 1997, approximately 800 different 
diagnostic tests were available, most of them for hereditary 
genetic disorders such as Tay – Sachs disease, sickle cell 
anemia, hemophilia, muscular dystrophy and cystic fibrosis. 
Amniocentesis, often called amnio, is recommended for 
women who will be older than 35 on their due-date. It is also 
recommended for women who have already borne children 
with birth defects, or when either of the parents has a family 
history of a birth defect for which a diagnostic test is available. 
Another reason for the procedure is to confirm indications of 
Down syndrome and certain other defects which may have 
shown up previously during routine maternal blood screening. 
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One of the most common reasons for performing 
amniocentesis is an abnormal alpha-fetoprotein (AFP) test. 
Alpha-fetoprotein is a protein produced by the fetus and 
present in the mother’s blood. A simple blood screening, 
usually conducted around the 15
th
 week of pregnancy, can 
determine the AFP levels in the mother’s blood. Levels that are 
too high or too low may signal possible fetal defects. Because 
this test has a high false-positive rate, another test such as 
amnio is recommended whenever the AFP levels fall outside 
the normal range. 
Amniocentesis is generally performed during the 16
th 
week of pregnancy, with results usually available within three 
weeks. It is possible to perform an amnio as early as the 11
th
 
week but this is not usually recommended because there 
appears to be an increased risk of miscarriage when done at 
this time. The advantage of early amnio and speedy results lies 
in the extra time for decision making if a problem is detected. 
Potential treatment of the fetus can begin earlier. Important, 
also, is the fact that elective abortions are safer and less 
controversial the earlier they are performed. 
As an invasive surgical procedure, amnio poses a real, 
although small, risk to the health of a fetus. Parents must weigh 
the potential value of the knowledge gained, or indeed the 
reassurance that all is well, against the small risk of damaging 
what is in all probability a normal fetus. The serious emotional 
and ethical dilemmas that adverse test results can bring must 
also be considered. The decision to undergo amnio is always a 
matter of personal choice. 
Procedure 
Before the start of the procedure, a local anesthetic can 
be given to the mother in order to relieve the pain felt during 
the insertion of the needle used to withdraw the fluid. After the 
local anesthetic is in effect, a needle is usually inserted through 
the mother’s abdominal wall, then through the wall of the 
uterus, and finally into the amniotic sac. With the aid of 
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ultrasound-guidance, a physician punctures the sac in an area 
away from the fetus and extracts approximately 20 ml of 
amniotic fluid. If used for prenatal genetic diagnosis, fetal cells 
are separated from the extracted sample. The cells are grown in 
a culture medium, then fixed and stained. Under a microscope 
the chromosomes are examined for abnormalities. The most 
common abnormalities detected are Down syndrome (trisomy 
21), Edwards syndrome (trisomy 18), and Turner syndrome 
(monosomy X). In regard to the fetus, the puncture heals and 
the amniotic sac replenishes the liquid over the next 24–48 
hours. 
 
 
          Figure 35 – A diagram of the technique of amniocentesis 
 
Indications and results 
1. Early in pregnancy, amniocentesis is used for 
diagnosis of chromosomal and other fetal problems such as: 
 Down syndrome (trisomy 21); 
 trisomy 13; 
 trisomy 18; 
 fragile X; 
 rare, inherited metabolic disorders; 
 neural tube defects (anencephaly and spina bifida) 
by alpha-fetoprotein levels. 
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2. Lung maturity. Amniocentesis can predict fetal lung 
maturity, which is inversely correlated to the risk of infant 
respiratory distress syndrome. In pregnancies of greater than 30 
weeks, the fetal lung maturity may be tested by sampling the 
amount of surfactant in the amniotic fluid. Several tests are 
available that correlate with the production of surfactant. These 
include the lecithin-sphingomyelin ratio (“L/S ratio”), the 
presence of phosphatidylglycerol (PG), and more recently, the 
surfactant/albumin (S/A) ratio. For the L/S ratio, if the result is 
less than 2:1, the fetal lungs may be surfactant deficient. The 
presence of PG usually indicates fetal lung maturity. For the 
S/A ratio, the result is given as mg of surfactant per gram of 
protein. An S/A ratio < 35 indicates immature lungs, between 
35–55 is indeterminate, and > 55 indicates mature surfactant 
production (correlates with an L/S ratio of 2.2 or greater). 
3. Infection, in which amniocentesis can detect a 
decreased glucose level, a Gram stain showing bacteria or an 
abnormal differential count of white blood cells. 
4. Rh incompatibility. 
5. Decompression of polyhydramnios. 
An emerging indication for amniocentesis is in the 
management of preterm rupture of membranes where 
measurement of certain amniotic fluid inflammatory markers 
may be helpful. If amniotic fluid IL-6, a marker of 
inflammation, is elevated, the fetus is at high risk and delivery 
should be considered. 
Risks and drawbacks 
Amniocentesis is performed between the 15
th
 and 20
th
 
week of pregnancy; performing this test earlier may result in 
fetal injury. The term “early amniocentesis” is sometimes used 
to describe use of the process between weeks 11 and 13. 
Complications of amniocentesis include preterm labour 
and delivery, respiratory distress, postural deformities, 
chorioamnionitis, fetal trauma and alloimmunisation of the 
mother (rhesus disease). Studies from the 1970s originally 
 128 
estimated the risk of amniocentesis-related miscarriage at 
around 1 in 200 (0.5 %). 
Social implications 
The prenatal diagnosis of chromosomal abnormalities 
can have social drawbacks as technology changes the way 
people think about disability and kinship. There is potential for 
intensification of attitudes of discrimination towards those with 
disability, whose births could have been prevented through 
technology such as amniocentesis. When reproduction 
becomes stratified, groups of people become disempowered to 
reproduce, and the standard of entry into human community is 
questioned. In one sense, amniocentesis offers a window of 
control, and in another – an anxiety-provoking responsibility to 
make rational decisions about complex, emotional and 
culturally contingent issues. 
 
Cordocentesis 
Percutaneous umbilical cord blood sampling 
(PUBS), also called cordocentesis, fetal blood sampling, or 
umbilical vein sampling is a diagnostic genetic test that 
examines blood from the fetal umbilical cord to detect fetal 
abnormalities. Fetal and maternal blood supply is typically 
connected in utero with one vein and two arteries to the fetus. 
The umbilical vein is responsible for delivering oxygen rich 
blood to the fetus from the mother; the umbilical arteries are 
responsible for removing oxygen poor blood from the fetus. 
This allows for the fetus’ tissues to properly perfuse. PUBS 
provides a means of rapid chromosome analysis and is useful 
when information cannot be obtained through amniocentesis, 
chorionic villus sampling, or ultrasound (or if the results of 
these tests were inconclusive); this test carries a significant risk 
of complication and is typically reserved for pregnancies 
determined to be at high risk for genetic defect. It has been 
used with mothers with immune thrombocytopenic purpura. 
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Procedure 
If the fetus is viable, the procedure is performed close 
to an operating room in case an emergency cesarean section is 
necessary due to complications caused by the procedure. 
Currently, there is no definite age of viability because this 
depends on the fetus’ ability to survive outside the womb, 
which in cases of premature births, can depend on access to 
medical care and technology needed to keep the fetus alive 
through the neonatal stage. Fetal viability typically occurs at 
about 24 to 25 weeks of gestation. When the fetus is in 
between the ages of 24–34 weeks, a glucocorticoid is given to 
the patient about 24 hours before the procedure to stimulate 
lung maturity. An ultrasound is performed before the procedure 
to view the position of the fetus and may be used during the 
procedure to help guide the needle. The mother’s blood is 
drawn for comparison against fetal blood, and intravenous 
access is established in the mother in order to supply 
medications as needed. To reduce the risk of intraamniotic 
infection, antibiotics are supplied through the intravenous 
access about 30–60 minutes before the procedure. If movement 
of the fetus is a risk to the success of the procedure, the fetus 
may be paralyzed using a fetal paralytic drug. 
A 20 or 22 gauge spinal needle is typically used in 
PUBS and may be prepared with an anticoagulant, which helps 
to reduce the risk of clot formation. During the procedure, the 
first step is to locate a relatively stable segment of the 
umbilical cord. A typical sampling site would be where the 
segment of the umbilical cord is closest to the placenta. 
However, there is a risk of maternal blood contamination at 
this site. Blood sampling may be achieved with more ease if 
the placenta is in the anterior position. However, if the placenta 
is in the posterior position, the fetus might block direct access 
to the umbilical cord. Once the umbilical cord is reached and 
the correct position of the needle is confirmed, the fetal blood 
is drawn. The needle is removed after all necessary samples are 
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taken. The site of puncture is monitored after the procedure for 
bleeding. Also, if the fetus is viable, fetal heart rate is 
monitored post-procedure for one to two hours. 
After the blood samples are obtained, they are placed 
into tubes containing anticoagulants in order to stop the blood 
from clotting. If the blood sample was obtained at the site close 
to the placenta, a fetal blood confirmation test should be done 
to ensure no mixing of fetal and maternal blood occurred 
before the diagnostic tests are done on the blood. Fetal red 
blood cells (RBC) are usually bigger than maternal RBCs, and 
the average volume of RBCs, the mean corpuscular volume 
(MCV), is one of the methods used to determine whether or not 
the fetal blood has been contaminated. Another method, human 
chorionic gonadotropin (HCG) determination, can detect 
maternal blood because maternal blood has high levels of 
HCG. The hemoglobin alkaline denaturation test (Apt test) can 
detect the presence of maternal blood, which is indicated by a 
colour change from red to brown when the sample is added to 
alkali reagent. Blood typing would also detect maternal blood, 
as the I antigen only occurs in adults. The Kleihauer – Betke 
test can detect very small amounts of maternal blood before the 
third trimester of pregnancy by monitoring hemoglobin elution 
in acid because adult and fetal hemoglobin elute differently in 
acid. Finally, a white blood cell count can detect maternal 
blood in the sample, as fetal white blood cells are primarily 
leukocytes, while maternal white blood cells are mostly 
neutrophils. If amniotic fluid infiltrated the sample, then there 
would be a reduction in the volume of RBCs, white blood cells, 
and platelets in the sample. Also, patterns consistent with 
amniotic fluid would be visible in the sample. 
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Figure 35 – Percutaneous umbilical cord sampling,  
also known as cordocentesis 
 
Associated risks 
The most common complication is a hemorrhage, or 
bleeding, of the puncture site and can be especially dangerous 
when the fetus is younger than 21 weeks. The risk of 
hemorrhage is greater if the fetus has a defect that affects its 
platelets. A transfusion of donor platelets is usually done in 
such cases to reduce the risk of bleeding. If the bleeding is 
severe, immediate delivery is an option as long as the fetus is 
old enough to survive, or fetal blood volume restoration may 
be considered. Another possible complication is cord 
hematoma, which doesn’t have any characteristic symptoms 
but can be indicated by sudden bradycardia. If the hematoma is 
under control, the fetus is monitored until stabilized. If the 
fetus remains unstable, a delivery may be done. Fetomaternal 
hemorrhage is another complication that occurs when the fetal 
blood mixes into the maternal blood. A small fetomaternal 
hemorrhage could cause an increase in maternal antigens, 
while a large fetomaternal hemorrhage could cause fetal 
anemia and death. Fetal bradycardia, low heart rate, is another 
complication that may occur. Most cases of fetal bradycardia 
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are self-resolved within five minutes. The complication of 
infection has a low incidence rate, and preventative measures 
are implemented against the risk of infection, such as antibiotic 
usage and the aseptic technique. However, vertical 
transmission of a virus such as HIV may occur. Fetal loss may 
also occur, especially in the presence of several risk factors, 
including fetal abnormalities, operator errors, placental 
penetration, and viability of the fetus. 
Intrahepatic vein fetal blood sampling may be done as 
an alternative to PUBS. It involves the needle being inserted 
into the intrahepatic part of the umbilical cord in the fetal 
abdomen.The benefits of this alternative, compared to PUBS, 
are that chances of contamination of the fetal blood are very 
low, the risk of fetomaternal hemorrhage is reduced, the risk of 
bleeding from the sampling site is reduced, and access to the 
sampling site is easy regardless of the position of the placenta. 
In pregnancies with high risk of fetal thrombocytopenia, this is 
the preferred method of blood samples due to the very low risk 
of site bleeding. 
Indications and contraindications 
PUBS is not a diagnostic test that is indicated in every 
pregnancy. It is, however, suggested in pregnancy cases in 
which the blood gas levels and pH would aid in diagnosis of a 
condition, such as anemia, or delivery plan, if termination of 
the pregnancy is being considered or special plans must be 
made. Severe fetal growth issues in conjunction with low 
oxygen in the fetus’ blood and high levels in the mother’s 
blood also indicate the use of PUBS. With more detailed 
observations and information on fetal tissue perfusion and 
metabolism, better predictions on development can be made. 
For pregnancies in which genetic abnormalities may be 
present, PUBS can be used to construct a karyotype, usually 
within 48 hours, and detect irregular chromosomal patterns. 
Karyotypes are able to confirm or detect monosomies, 
trisomies, or missing portions of chromosomes to give a 
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detailed picture of the severity of the genetic defect as well as 
predicting developmental future. PUBS is also indicated in the 
cases of twins with accumulation of amniotic fluid and 
substantially different growth rates (at least 10 %), if the fetus 
is expected to be breaking down red blood cells improperly, 
and in the alleviation of hydrops fetalis, a build-up of fluid in at 
least 2 parts of the fetus. Suspicion of fetal infections, such as 
rubella and toxoplasmosis, as well as the need to supply 
medicine or blood transfusions to the fetus are indications for 
the use of PUBS. 
Due to its invasive nature, the contraindications of 
PUBS, reasons to not undergo the procedure, must be taken 
into account in order to ensure the safety of the fetus and the 
mother. During the first 18 weeks of pregnancy, the umbilical 
vein from which the blood sample is taken is not very stable, 
which could lead to excessive bleeding; therefore, PUBS is 
contraindicated in any fetus under the age of 18 weeks old. 
While blood gas levels and pH values are able to give parents 
and medical professionals a snapshot of fetal status, these 
fetuses can be monitored with less invasive procedures and 
equipment, such as ultrasounds, cardiotocography, or maternal 
blood tests. Mothers affected by hepatitis B are not advised to 
undergo PUBS. In these cases, the fetus would be put at an 
increased risk of contracting the hepatitis virus from the 
mother. However, the necessity of the procedure should be 
considered along with this risk. PUBS should not be performed 
in mothers testing positive for the human immunodeficiency 
virus (HIV) due to increased risk of fetal contraction. If PUBS 
is being used to determine if the fetus has been infected with 
HIV it may not be contraindicated 
Fetoscopy 
Fetoscopy is a procedure that utilizes an instrument 
called a fetoscope to evaluate or treat the fetus during 
pregnancy. 
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There are two different types of fetoscopy: external and 
endoscopic. 
External fetoscopy  
An external fetoscope resembles a stethoscope, but with 
a headpiece. It is used externally on the mother’s abdomen to 
auscultate (listen to) the fetal heart tones after about 18 weeks 
gestation. It also allows a birth attendant to monitor the fetus 
intermittently and ensure that the baby is tolerating labour 
without the mother having to be attached to a continuous fetal 
monitor. 
Endoscopic fetoscopy  
The second type of fetoscope is a fiber-optic endoscope. 
It is inserted into the uterus either transabdominally (through 
the abdomen) or transcervically (through the cervix) to 
visualize the fetus, to obtain fetal tissue samples, or to perform 
fetal surgery. 
Approximately 3 % of babies born each year have a 
complex birth defect. Certain birth defects are complicated by 
the labour and delivery process, while others may progress 
quickly after birth to cause significant disability or death. Fetal 
surgical techniques utilizing the endoscopic fetoscope offer 
early intervention in order to treat such defects before they 
become serious. 
Some of the fetal abnormalities that may be treated by 
endoscopic fetoscopy are: 
 Congenital diaphragmatic hernia (CDH). In babies 
with CDH, the diaphragm (the thin muscle that separates the 
chest from the abdomen) doesn’t develop properly. The 
abdominal organs may enter the chest cavity through a hole 
(hernia) and cause pulmonary hyperplasia (underdeveloped 
lungs). CDH occurs in about one out of every 2 000 births. 
 Urinary tract obstruction. The urethra (the tube that 
carries urine from the bladder to the outside of the body) may 
become obstructed in utero or fail to develop normally. When 
this happens, urine can back up into the kidneys and destroy 
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tissue or cause the bladder to become enlarged. The amount of 
amniotic fluid also decreases because fetal urine is its major 
component. 
 Pulmonary hypoplasia usually results because the 
lungs rely on amniotic fluid in their development. 
 Twin/twin transfusion syndrome (TTTS). In some 
twin pregnancies, the two fetuses will share a placenta (called 
a monochorionic pregnancy).  TTTS  occurs in approximately 
15 % of these twins when blood volume between the fetuses is 
unequal, causing abnormally low blood volume in the donor 
twin and abnormally high blood volume in the recipient twin. 
There is often a large difference in size between the twins. 
Approximately 70–80 % of fetuses suffering from TTTS will 
die without intervention. 
 Acardiac twin. This condition also occurs in 
monochorionic pregnancies, but one twin develops normally 
while the other develops without a heart. The acardiac twin 
receives its blood supply from the normal twin, whose heart 
must now work harder to pump blood through both fetuses. 
Approximately 50–75 % of acardiac twins will die as a result. 
An acardiac twin occurs in 1 % of monochorionic pregnancies 
and one out of 35 000 overall pregnancies. 
The external fetoscope is used to listen to fetal heart 
tones for rate and rhythm. The earpieces and the headpiece 
allow auscultation (listening) via both air and bone conduction. 
External fetoscopy is inexpensive, noninvasive, and does not 
require electricity. It is difficult, however, to clearly hear the 
fetal heart tones prior to 18 to 20 weeks gestation. Doppler 
ultrasound can detect fetal heart tones around weeks 10 to 12. 
Endoscopic fetoscopy uses a thin (1 mm) fiberoptic 
scope. Developed in the 1970s, the endoscope was originally 
inserted transabdominally to visualize the fetus for gross 
abnormalities suspected by ultrasound or to obtain tissue and 
blood samples. It was performed after about 18 weeks of 
gestation. Even with practitioner expertise, associated fetal loss 
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was 3–7 %. During the 1980s, ultra-sound-guided needle 
sampling of cord blood replaced fetoscopy when samples of 
fetal blood were required. 
As laparoscopic and microsurgical techniques have 
become more common and the instrumentation has become 
more advanced technologically, fetoscopy has improved for 
fetal diagnostic and therapeutic purposes. Fetal surgery 
performed through an open maternal abdomen has a higher risk 
of such complications as infection, premature rupture of 
membranes, preterm labour, or fetal death. If surgery is 
performed via fetoscopy, which requires a very small 
transabdominal incision, the risks are much smaller. 
Techniques have advanced enough to allow some fetoscopy to 
be performed in the first trimester via the mother’s cervix. The 
term “obstetrical endoscopy” may be used for surgery on the 
placenta, umbilical cord, or on the fetal membranes. The term 
“endoscopic fetal surgery” is used for such procedures as the 
repair of a fetal congenital diaphragmatic hernia or obstructed 
bladder. 
Diagnosis/Preparation 
The use of external fetoscopy requires access to the 
maternal abdomen, with the mother lying supine or in a semi-
seated position. Afterwards, the mother is able to get up and 
resume a normal activity level. 
Preparation for endoscopic fetoscopy will depend on 
the extent of the procedure, and whether it is performed 
transcervically or transabdominally. Obtaining a small fetal 
tissue sample is a smaller procedure by comparison to fetal 
surgery. Other factors include outpatient versus inpatient stay 
and anesthesia (both maternal and fetal). For some procedures 
medication may be administered to temporarily decrease fetal 
movement to lower the risk of fetal injury. Maternal anesthesia 
may be local, regional, or general. 
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Figure 36 – Fetoscopy 
 
Aftercare 
External fetoscopy does not require aftercare. The care 
following fetal endoscopic use will depend on the extent of the 
procedure and the type of anesthesia used. If the procedure is 
done on an outpatient basis, the mother and fetus will be 
monitored for a period of time prior to discharge. More 
extensive surgery will require inpatient hospital postoperative 
care. 
Risks 
The only potential complication with external fetoscopy 
is the possibility of missing an abnormal heart rate or rhythm. 
Its usefulness and accuracy depend on the skill of the 
practitioner. 
Endoscopic fetoscopy has the potential for causing 
infection in the fetus and/or mother; premature rupture of the 
amniotic membranes; premature labour; and fetal death. When 
endoscopic fetal surgery is done instead of open-uterus fetal 
surgery, the risks to the mother and fetus are decreased. The 
risks are because the incision is significantly smaller, with less 
potential blood loss, decreased uterine irritability, and 
decreased risk of early miscarriage. 
 
 
 138 
Normal results 
The normal fetal heart rate is 120 to 160 beats per 
minute, regardless of the method used for auscultation 
(external fetoscopy or Doppler ultrasound). Some variability of 
fetal heart rate is expected, as the heart rate increases with fetal 
activity and slows with fetal rest. 
Results expected using endoscopic fetoscopy will vary 
depending on the procedure undertaken. The goal is for the 
maximum benefit with the minimum of risk or complication to 
both the mother and fetus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
REFERENCES 
 
1. Modern    methods    of    genetic     diagnosis     /   
V. E. Markevich, V. O. Petrashenko, O. K. Redko [et al.] // 
Sumy : Sumy State University, 2015. – 214 p. 
2. Grechanina O. Y. Inherited diseases of connective 
tissue / O. Y. Grechanina // Ulitrasoung perinatal diagnostic, 
2001. – 14 p. 
3. Nelson Textbook of Pediatrics, 20
th
 edition / Robert 
M. Kliegman, Bonita F. Stanton, Nina F. Schor [et al.] // 
London : Elsevier, 2016. – 3880 p. 
4. Nussbaum R. Genetics in Medicine / R. Nussbaum, 
R. McInnes, H. Willard. – Baltimore : Elsevier, 2016. – 560 p.  
5. Jorde L. B. Medical Genetics / Lynn B. Jorde, John 
C. Carey, Michael J. Bamshad. – Baltimore : Elsevier, 2016. – 
368 p.  
6. Fuhrman B. P.   Pediatric  Critical   Care  /   Bradley  
P. Fuhrman, Jerry J. Zimmerman. – Baltimore : Elsevier,  
2017. – 1960 p. 
 140 
Навчальне видання 
 
 
 
Петрашенко Вікторія Олександрівна, 
Лобода Андрій Миколайович, 
Касян Світлана Миколаївна 
 
 
 
Медична генетика 
 
Навчальний посібник 
(Англійською мовою) 
 
За загальною редакцією С. В. Попова 
 
 
 
Художнє оформлення обкладинки В. О. Петрашенко 
Редактори: Л. В. Штихно, О. О. Кучмій 
Комп’ютерне верстання В. О. Петрашенко 
 
 
 
Формат 60х84/16. Ум. друк. арк. 8,14. Обл.-вид. арк. 9,45. Тираж 300 пр. Зам. № 
 
 
 
Видавець і виготовлювач   
Сумський державний університет, 
вул. Римського-Корсакова, 2, м. Суми, 40007 
Свідоцтво суб’єкта видавничої справи  ДК № 3062 від 17.12.2007. 
